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SUMMARY 
Splicing of pre-mRNA is a crucial regulatory stage in the pathway of gene 
expression. The majority of human genes that encode proteins undergo alternative 
splicing, being now known that mutations affecting splicing are more prevalent than 
previously thought. According to some estimates up to 50-60% of all pathogenic 
mutations may affect splicing in some way. Thus, the development of therapeutic 
strategies targeting RNA represents an important opportunity to correct faulty splicing, 
opening the prospects of treatment for numerous genetic disorders. The vast majority 
of RNA-based approaches have exploited, in vitro and in vivo, antisense 
oligonucleotide sequences to either block the use of natural or new splice sites, 
inducing the skipping of defective exons, or blocking the newly generated cryptic sites 
to favour the use of the canonical ones. On the other hand, the use of U1 snRNA 
complementary to the mutated site has been described as a potentially therapeutic 
strategy to correct 5’ splice donor site (SDS) defects dependent on U1 binding. 
Following the rule, many splicing mutations have been identified in cohorts of 
patients with Lysosomal Storage Disorders (LSDs), a group of approximately 50 
inherited metabolic diseases, usually associated with severe and progressive 
phenotypic manifestations due to specific lysosomal dysfunctions. Some treatment 
strategies are already available for conventional LSDs, but yet with some limitations. 
Therefore, in the case of LSDs, therapeutics directed to splicing mutations might 
represent a crucial option or an important adjunct of other treatments. 
In this work attention was focused on the analysis of mechanisms disrupting 
splicing in a set of mutations involved in the pathogenesis of LSDs, and on the design 
and development of RNA-based therapies for the correction of the effects of some of 
those mutations. 
The IDS gene encodes iduronate-2-sulphatase, an enzyme deficient in the X-
linked lysosomal storage disorder - Mucopolysaccharidosis type II (MPS II). For the 
three nucleotide changes in the IDS gene associated with disease; the missense 
mutation c.257C>T, the nonsense c.241C>T (both in exon 3) and the synonymous 
c.1122C>T (exon 8), transcript analysis and minigene functional assays revealed that 
the first two cause the pathogenic activation of a 3’ cryptic splice site in exon 3, 
whereas c.1122C>T leads to the creation of a new 5’ splice site in exon 8. The cryptic 
splice site activation in exon 3 suggests that the use of its 3’ constitutive splice site 
requires the interaction of several auxiliary trans-acting factors whose cis-binding 
motifs were changed by the mutations. Given these findings, an in silico analysis was 
performed to search for mutation-induced alterations in auxiliary elements located in 
IDS exon 3. The elimination of a binding motif for the SRSF2 and hnRNP E1 and E2 
splicing factors and the creation of one for the SRSF1 protein was predicted for the 
missense mutation, c.257C>T. The overexpression of the SRSF2 and hnRNP E1 
proteins along with the mutant minigene, as well as an assay with other minigene 
presenting the deletion of a 6-base pair sequence which comprises the predicted cis-
acting motifs for the binding of these proteins showed that they may be involved in the 
use and repression of the constitutive 3’ splice site of exon 3, respectively. 
For the synonymous mutation c.1122C>T which creates a new 5’ splice site 
within exon 8 causing the deletion of its last 60 base pairs, we investigated the 
applicability of antisense therapy to correct the splicing defect. Yet, transfection of three 
antisense morpholino oligonucleotides (AMO) and one locked nucleic acid (LNA) in 
patient fibroblasts did not abolish the abnormal transcript, resulting in addition in the 
production of a new aberrant splicing product. Also, the antisense oligonucleotides 
transfection in control fibroblasts produced the same aberrant transcript detected in 
patient cells following treatment, evidencing that the oligonucleotides are masking 
important cis-acting elements for the 5’ splice site regulation of exon 8. These results 
pointed out that the development of antisense therapies remains a challenge in genes 
under fine splicing regulation, as appears to be IDS.  
In this work we also explored the use of different modified U1 snRNAs to correct 
three SDS mutations (c.234+1G>A, c.633+1G>A and c.1542+4dupA) reported in 
patients with Mucopolysaccharidosis type IIIC (MPS IIIC), a LSD caused by mutations 
in the HGSNAT, which encodes the enzyme acetyl CoA: α-glucosaminide 
acetyltransferase. The partial correction (almost 50%) of c.234+1G>A (intron 2) was 
achieved in patients fibroblasts with a modified U1 snRNA matching all the nucleotides 
of the mutated SDS. In the case of the other mutations, no rescue was observed after 
the modified U1 snRNAs overexpression.  
Finally, we developed antisense oligonucleotide and U1 snRNA-mediated 
therapeutic strategies for the correction of a SDS mutation in the CSTB gene, which 
encodes cystatin B, a key protein in the protection against the proteinases leaking from 
lysosomes, whose deficiency is associated with the most common form of progressive 
myoclonic epilepsy: Unverricht-Lundborg disease (ULD). The synonymous mutation 
here studied, c.66G>A, located in the last nucleotide of the exon 1, causes the partial 
inclusion of intron 1 due to the activation of a cryptic splice site inside the intron. A 
specific LNA oligonucleotide designed to block the 5’ cryptic splice site allowed to 
recover the normal splicing pattern in patient cells, although the therapeutic effect was 
shown to be dose-dependent. Concerning the U1 approach, the transfection of different 
adapted U1 vectors failed to restore correct splicing. A careful analysis of the wild-type 
and mutant exon 1 SDS suggested that splicing regulation around this exon depends 
not only on the U1 snRNA binding but also on other splicing factors that could interact 
with the CSTB pre-mRNA compromising the success of the therapy.  
Globally, the results obtained in this work allowed to clarify some aspects of the 
basic molecular mechanisms underlying the pre-mRNA splicing and its dysregulation in 
the presence of splicing mutations, further contributing to pave the way for innovative 
RNA-based therapeutic strategies that could ultimately result in patient-tailored 
correction of splicing mutations.  
 
KEY WORDS: Lysosomal Storage Disorders (LSDs), Splicing regulation, Antisense 
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RESUMO 
O splicing do pré-mRNA é um processo fundamental para a regulação da 
expressão génica. A maioria dos genes humanos codificadores de proteínas apresenta 
splicing alternativo, sabendo-se hoje que mutações que interferem com o splicing 
conduzindo à produção de proteínas anormais e/ou deficientes são mais frequentes do 
que inicialmente previsto. De acordo com algumas estimativas, cerca de 50 a 60% de 
todas as mutações patogénicas descritas afetam de alguma forma o processo. Assim, 
o desenvolvimento de terapias que têm por alvo o RNA representa uma importante 
oportunidade de correção direcionada de erros de splicing, abrindo perspetivas de 
tratamento a um grande número de doenças genéticas. 
 A grande maioria destas abordagens tem explorado in vitro ou in vivo, o uso de 
oligonucleótidos antisense com o objetivo de bloquear locais de splicing constitutivos 
ou criados de novo, induzindo desta forma o skipping de exões que apresentam 
mutações patogénicas ou o bloqueio de locais aberrantes de splicing promovendo a 
utilização dos locais convencionais. Por outro lado, o uso de vetores U1 snRNA com 
diferentes complementaridades de ligação ao local mutado na região 5’ do splicing, 
tem sido considerado uma promissora abordagem terapêutica para a correção de 
mutações que afetam a ligação do U1 snRNA. 
Não fugindo à regra, mutações que alteram o processo de splicing também se 
encontram em doentes diagnosticados com Doenças Lisossomais de Sobrecarga 
(DLS). As DLS são um grupo de cerca de 50 doenças hereditárias do metabolismo 
geralmente caracterizadas pela apresentação de um fenótipo grave e progressivo 
devido a uma disfunção lisossomal específica. Atualmente estão disponíveis algumas 
estratégias de tratamento, mas dirigidas a um pequeno número de DLS e sempre 
associadas a sérias limitações. Assim, no caso destas patologias, o desenvolvimento 
de abordagens terapêuticas baseadas na correção do splicing pode constituir uma 
opção de maior relevância, quer individualmente, quer como adjuvante de tratamento. 
Este trabalho teve como objetivos principais: 1) analisar os mecanismos de 
splicing e sua desregulação na presença de mutações envolvidas na patogénese 
lisossomal, e 2) contribuir para o desenvolvimento de abordagens terapêuticas 
baseadas na correção dos efeitos causados por algumas dessas mutações.  
O gene IDS codifica a enzima iduronato-2-sulfatase, cujo défice causa a 
Mucopolissacaridose tipo II (MPS II), uma DLS com modo de transmissão ligado ao X. 
Relativamente a três alterações nucleotídicas no gene IDS associadas a doença - a 
mutação missense c.257C>T, a nonsense c.241C>T (ambas localizadas no exão 3) e 
a mutação sinónima c.1122C>T (exão 8) - a caracterização dos respetivos transcritos 
e a análise funcional através de minigenes permitiram verificar que as mutações 
c.257C>T e c.241C>T causavam a ativação patogénica de um local de splicing críptico 
localizado na extremidade 3’ do exão 3, e que a alteração c.1122C>T estava na 
origem da criação de um novo local de splicing na região 5’ do exão 8. A ativação do 
local críptico no exão 3 sugere que o uso do local de splicing constitutivo a 3’ requer a 
interação de vários elementos cis-acting e fatores trans-acting que devem ter sido 
alterados pela presença destas mutações. Foi então efetuada uma análise in silico 
para as duas mutações do exão 3, permitindo prever que a eliminação de um motivo 
de ligação para os fatores de splicing SRSF2 e hnRNP E1 e E2, assim como a criação 
de um motivo de ligação para o fator SRSF1 ocorreriam na presença da mutação 
c.257C>T. Os resultados tanto da sobrexpressão das proteínas SRSF2 e hnRNP E1 
em co-transfeção com um minigene que continha a sequência mutada, como de um 
ensaio com um minigene onde foi efetuada a deleção de uma sequência de 6 pares de 
bases que inclui os motivos cis-acting previstos para a ligação destas proteínas, 
indicaram que ambas as proteínas poderão estar envolvidas respetivamente, no uso e 
repressão do local de splicing constitutivo a 3’ do exão 3.  
No caso da mutação sinónima c.1122C>T, que origina um novo local de splicing 
a 5’ no exão 8 causando a deleção dos seus últimos 60 pares de bases, a 
aplicabilidade da terapia antisense foi investigada com o objetivo de corrigir o defeito 
de splicing. Contudo, a transfeção de fibroblastos de um doente com três 
oligonucleótidos antisense do tipo morpholino e de um oligonucleótido do tipo locked 
nucleic acid (LNA) não permitiu a eliminação do transcrito anormal, resultando até na 
produção de um novo transcrito aberrante. Para além disso, a transfeção dos mesmos 
oligonucleótidos em fibroblastos de um controlo originou o mesmo transcrito aberrante 
observado nas células do doente após o tratamento, demonstrando que os 
oligonucleótidos ocultaram importantes motivos cis-acting envolvidos na regulação do 
local 5’ de splicing do exão 8. Estes resultados evidenciam não só a complexidade da 
regulação do splicing no gene IDS, como a dificuldade em desenvolver com sucesso, 
em casos deste tipo, terapêuticas dirigidas à correção de anomalias no processo.  
Neste trabalho também foi explorado o uso de diferentes vetores U1 snRNA 
modificados para a correção de três mutações que afetam o local 5’ de splicing 
(c.234+1G>A, c.633+1G>A e c.1542+4dupA) presentes em doentes com 
Mucopolissacaridose tipo IIIC (MPS IIIC), um tipo de DLS causada por mutações no 
gene HGSNAT que codifica a enzima Acetil-CoA: α-glicosamina-N-acetiltransferase. A 
correção parcial (cerca de 50%) da mutação c.234+1G>A (intrão 2) foi conseguida em 
fibroblastos de um doente com a utilização de um vetor U1 snRNA modificado que 
emparelhava na totalidade com o local 5’ de splicing mutado. Para as restantes 
mutações, após a sobrexpressão de diferentes vetores U1 snRNA não se observou a 
reversão do padrão de splicing aberrante.  
Por fim, ensaiou-se a correção de uma mutação que afeta um local 5’ de splicing 
no gene CSTB, codificador da proteína cistatina B que desempenha um papel 
importante na proteção celular contra a ação de proteases lisossomais. O défice desta 
proteína encontra-se associado à forma mais comum de epilepsia mioclónica 
progressiva, a doença de Unverricht-Lundborg. A alteração sinónima alvo deste 
estudo, c.66G>A localiza-se no último nucleótido do exão 1 do gene CSTB e a sua 
presença leva à inclusão parcial do intrão 1 devido à ativação de um local de splicing 
críptico a 5’. Um oligonucleótido do tipo LNA especificamente desenhado para 
bloquear o local críptico a 5’ permitiu recuperar o normal padrão de splicing nas 
células de um doente, embora o efeito terapêutico fosse dependente da dose de 
oligonucleótido. Recorreu-se também a outra abordagem com vetores U1 snRNA 
modificados, que após transfeção não permitiram obter qualquer correção do splicing 
aberrante. A análise detalhada dos locais 5’ de splicing wild-type e mutado do exão 1 
revelou que a regulação do splicing envolvendo este exão depende não só da ligação 
do U1 snRNA, como também de outros fatores de splicing que poderão interagir com o 
pré-mRNA do gene CSTB comprometendo assim o sucesso da terapia com estes 
vetores.  
Globalmente, os resultados obtidos com a realização deste trabalho permitiram 
clarificar alguns aspetos do mecanismo molecular subjacente ao processo de splicing 
e sua desregulação na presença de mutações, assim como avançar no caminho 
inovador do desenvolvimento de abordagens terapêuticas baseadas na correção do 
splicing que poderão ser aplicadas de forma personalizada em doentes portadores de 
mutações de splicing.  
 
PALAVRAS-CHAVE: Doenças Lisossomais de Sobrecarga (DLS), Regulação do splicing, 
Terapia com oligonucleótidos antisense, Terapia mediada por vetores U1 snRNA.  
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1.1 Regulation of gene expression and the splicing 
process 
Since in the late 1950s it was stated that DNA makes RNA and RNA makes 
proteins (Crick, 1958; Crick, 1970), much research was done to uncover how each step 
in the sequential transfer of information from nucleic acids to protein works (Gottlieb, 
2003). The understanding of gene structure, expression and function has provided 
fundamental insights into the molecular biology of cells. Over the time it has become 
clear that cell behaviour is determined not only by the genes, but importantly, also by 
which of them are expressed at any given time. Expression of eukaryotic genes is a 
multistep process that includes transcription of the gene, 5’ -end capping and 3’ -end 
polyadenylation of the primary transcript, splicing and transport of the fully processed 
messenger RNA (mRNA) to the cytoplasm, where it can be translated into protein. 
Regulation of gene expression allows cells to adapt to changes in their environments 
and is responsible for the distinct activities of the multiple differentiated cell types that 
make up complex plants and animals (Cooper & Hausman, 2013; Singer & Green, 
1997). 
One of the most important stages in the chain of processes from DNA to protein 
is pre-mRNA splicing. Firstly identified in the late 1970s with the discovery of introns 
(Berget et al., 1977; Chow et al., 1977), pre-mRNA splicing is a highly regulated step-
wise process in which intron sequences are removed and exons are joined together to 
generate a mature protein-coding mRNA transcript (the so-called constitutive splicing). 
Splicing reactions can be alternative, since exons and introns can be excised or 
included in variable ways in the final mRNA product. Alternative splicing (AS) is 
predicted to occur in the vast majority of mammalian genes, being a primary 
mechanism through which complex organisms can regulate protein expression and 
generate a diverse proteome from a relatively limited genome (De Conti et al., 2013; 
House & Lynch, 2008; Kelemen et al., 2013).  
 
1.1.1 Core splicing signals and spliceosome assembly  
The splicing reaction is carried out by the spliceosome, a dynamic molecular 
machine, which consists of five small nuclear ribonucleoprotein complexes (snRNPs) 
U1, U2, U4, U5 and U6, and up to 300 different structural proteins. Two of the main 
functions of the spliceosomal snRNPs are to recognise and interact with specific 
sequence elements (splicing signals) at the exon/intron boundaries such as the 5’ and 
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3’ splice sites (ss), branch point sequence (BPS) and polypyrimidine tract (PPT) 
(Figure 1.1A), and to engage the spliceosomal complex to catalyze an efficient splicing 
reaction. Spliceosome assembly (Figure 1.1B) begins with the recognition of the 5′ ss 
by the U1 snRNP and the binding of splicing factor 1 (SF1) to the branch point and of 
the U2 auxiliary factor heterodimer (U2AF65/35) to the polypyrimidine tract and 3′ 
terminal AG. This assembly is ATP-independent and results in the formation of the E 
complex, which is converted into the ATP-dependent, pre-spliceosomal A complex 
after the replacement of SF1 by the U2 snRNP at the branch point. Further recruitment 
of the U4/U6•U5 tri-snRNP leads to the formation of the B complex. This is followed by 
extensive conformational changes and remodelling, including the loss of U1 and U4 
snRNPs, ultimately resulting in the formation of the C complex, which is the active 
spliceosome capable of catalyzing the transesterification chemistry required for exon 
ligation and lariat release (Chen & Manley, 2009; De Conti et al., 2013; Matera & 
Wang, 2014). Although the spliceosome catalyzes RNA cleavage and ligation with high 
fidelity, the inherent flexibility of this enzymatic complex allows it to be highly sensitive 
to regulation. Such flexibility has played a fundamental role in the evolution of higher 
organisms by promoting proteome expansion and helping to regulate gene expression 
(De Conti et al., 2013; House & Lynch, 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: A) The architecture of a pre-mRNA and the important cis-acting sequence elements that direct the splicing 
reaction. The consensus sequences at the 5’ ss, BPS and 3’ ss are as indicated, where N is any nucleotide, R is a 
A 
B 
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purine and Y is a pyrimidine. The polypyrimidine tract (Py) is a pyrimidine-rich stretch located between the BPS and the 
3’ ss.  B) Schematic representation of spliceosome assembly and the splicing of a pre-mRNA. The first step in 
spliceosome assembly is the formation of early (E) or commitment complex in which the 5’ ss is bound by the U1 
snRNP and the splicing factors SF1 and U2AF cooperatively recognise the BPS, the Py and the 3’ ss. This pairing is 
stabilized by addition of ATP, which allows binding of the U2 snRNP to the BPS  to form the A complex. The U4/U6•U5 
tri-snRNP then joins as a single unit to form the B complex. Multiple ATP-dependent rearrangements result in the 
release of the U1 and U4 snRNPs and formation of the C complex, which catalyzes excision of the intron as a lariat and 
ligation of the exon sequences. Adapted from(Hartmann et al., 2008; Rymond, 2007; Wahl et al., 2009) 
 
1.1.2 Exon recognition – a key multifactorial step in splicing 
regulation 
A critical challenge to the spliceosome is to correctly identify exons within the pre-
mRNA. Exons make up only one-tenth of the typical pre-mRNA and therefore must be 
identified within a sea of introns. Despite the splicing mechanism has been determined 
in great detail, it is not yet fully understood how splice sites are selected. The major 
problem is the degeneracy of splicing regulatory sequences, such as the 5’, 3’ ss, 
branch point and exonic/intronic sequence elements. These can only be described as 
consensus sequences that are necessary but not sufficient for defining intron-exon 
junctions (Hertel, 2008; Stamm et al., 2005; Ward & Cooper, 2010). Thus, the accurate 
mechanism of exon recognition in vivo is now believed to be the result of a complex 
combinatorial control depending on multiple parameters such as splice site strength, 
the presence or absence of splicing regulators (silencer or enhancer sequences), the 
exon/intron architecture, RNA secondary structures, transcriptional processivity by 
RNA polymerase II (pol II), nucleosome positioning and histone modifications at the 
chromatin level. Depending on local contexts, all these factors will act either 
antagonistically or synergistically to decide the exon/intron fate of any given RNA 
sequence (De Conti et al., 2013; Hertel, 2008; Kornblihtt et al., 2013; Wang & Burge, 
2008). The factors that present greater relevance for this work will be considered in 
more detail in the following sections. 
 
1.1.2.1 Splice site strength and gene architecture roles in exon-
intron definition 
The adjacent nucleotides at each splice site comprise two easily distinguished 
consensus sequences: the 5’ ss junction defined by a single element of 9 bases and 
the 3’ ss loosely defined by three sequence elements (branch point sequence, 
polypyrimidine tract and the 3’ exon/intron junction), which may extend 40 nucleotides 
into the intron, upstream to the 3’ exon/intron junction (Reed, 1996). The initial 
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recognition of exon/intron junctions is based on the relative strength of the splice sites 
(i.e., how near to consensus is their sequence) that play a major role in determining 
whether the basic snRNP factors will be able to interact and bind. Because the 
sequence specificity of the splice site/snRNP binding is driven by their interaction level 
and the U2 auxiliary factor binding preference for polypyrimidines, splice sites are 
classified by their complementarity to U1 snRNA (small nuclear RNA) (5’ ss) and the 
extent of the polypyrimidine tract (3’ ss). Greater complementarity with U1 snRNA and 
longer polypyrimidine tracts translate into higher affinity binding sites for these 
spliceosomal components and thus more efficient exon recognition (De Conti et al., 
2013; Hertel, 2008). 
Most human genes contain relatively short exons (typically, 50-250 base pairs in 
length) separated by much larger introns (frequently hundreds to thousands of base 
pairs) that on average account for >90% of the primary transcript (Chen & Manley, 
2009; Wang & Burge, 2008). This relative length of introns and exons – exon/intron 
architecture – has also been shown to have an influence on splice site recognition 
(Berget, 1995). Early experiments aimed to investigate the influence of exon and intron 
sizes in vertebrate pre-mRNA processing showed that enlarged exons lead to exon 
skipping, but if the flanking introns are short, the enlarged exon is included (Sterner et 
al., 1996). Therefore, splice site recognition seems to be more efficient when introns or 
exons are small. These observations suggested that splice sites are recognised across 
an optimal nucleotide length, meaning thus that intron length might significantly 
influence the efficiency of pre-mRNA splicing and alternative splice site choice. On this 
ground, two models were proposed for the mechanism of exon and intron selection: 
“intron definition” and “exon definition”. The “intron definition” model posits that 
interactions occur first across the intron between factors recognizing the 5’ ss and the 
downstream 3’ ss, whereas the alternative model, “exon definition”, sustains that the 
splice sites flanking the exon are initially recognised and subsequently paired (Berget, 
1995). The higher GC content in exons relative to their flanking introns is presumed to 
be the signal that allows exons to be identified (Keren et al., 2010). Considering that in 
the human genome the vast majority of the exons are short and introns are long it is 
likely that most of the human splice sites are recognised across the exon (Sakharkar et 
al., 2005). In fact, coevolution analyses of the 5’ and 3’ ss have detected predominant 
cross-exon interactions in human and mouse, but cross-intron interactions in 
invertebrates, plants, and fungi, supporting the primacy of exon definition in mammals 
and intron definition in most other metazoans (Xiao et al., 2007). On a practical level, 
however, it is important to bear in mind that there is no mechanistic difference in 
spliceosomal complex assembly over exons or introns and that both exon definition 
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and intron definition may occur in different parts of the same pre-mRNA (De Conti et 
al., 2013).  
With the increasing knowledge on the process, several bioinformatic algorithmic 
models have been developed to calculate the splice site consensus values (i.e. to 
predict the splice site strength). Presently, there are several online tools that analyse 
the strengths of splice sites and the changes induced by different sequence variations 
(e.g. mutations). The more widely used are: GENSCAN, available at 
http://genes.mit.edu/GENSCAN.html (Burge & Karlin, 1997), Splice Site Prediction by 
Neural Network, available at http://www.fruitfly.org/seq_tools/splice.html (Reese et al., 
1997), MaxEntScan, available at http://genes.mit.edu/burgelab/maxent/Xmaxentscan 
_scoreseq.html (Yeo & Burge, 2004), and Human Splicing Finder, available at 
http://www.umd.be/HSF/ (Desmet et al., 2009).  
 
1.1.2.2 The role of cis-acting elements and trans-acting factors 
in exon-intron definition 
Besides the core splicing signals, additional sequences are needed in exons and 
introns to increase the overall fidelity of the splicing reaction. Indeed, it is now widely 
accepted that the majority of pre-mRNA molecules contains a myriad of auxiliary cis-
acting regulatory elements that either enhance or inhibit exon-intron recognition. These 
elements are conventionally classified as exonic splicing enhancers (ESEs) or 
silencers (ESSs) if from an exonic location they function to promote or inhibit inclusion 
of the exon they reside in, and as intronic splicing enhancers (ISEs) or silencers (ISSs) 
if they enhance or inhibit usage of adjacent splice sites or exons from an intronic 
location (Figure 1.2) (Chen & Manley, 2009; De Conti et al., 2013; Kornblihtt et al., 
2013; Wang & Burge, 2008). In general, these splicing regulatory elements (SREs) 
share several common features: they are small (6-8 nucleotides), individually weak, 
and present in multiple copies. They are often conserved between species and 
perhaps between similarly regulated genes, but they contain degenerate sequence 
motifs, making it difficult to identify them (Hartmann et al., 2008; Jensen et al., 2009; 
Ladd & Cooper, 2002). Enhancers and silencers are involved in both constitutive and 
alternative splicing and function by recruiting trans-acting splicing factors that activate 
or supress splice site recognition or spliceosome assembly by various mechanisms (De 
Conti et al., 2013; Wang & Burge, 2008). The ESE motifs are usually recognised by 
members of the SR (serine/arginine) protein family that act as positive regulators 
promoting exon inclusion. These trans-acting proteins are characterized by having one 
or more RNA recognition motifs (RRMs) as well as an RS (arginine/serine-rich) domain 
36 FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
 
responsible for protein–protein interactions (Busch & Hertel, 2012; De Conti et al., 
2013; Jensen et al., 2009; Risso et al., 2012; Shepard & Hertel, 2009). Unlike ESEs, 
the proteins that mediate the effect of ISEs are less well characterized although several 
tissue-specific proteins, such as NOVA (Jelen et al., 2007; Ule et al., 2006) and FOX2 
(Yeo et al., 2009) have been shown to bind ISEs and to stimulate splicing.  
On the other hand, negative regulation of exon recognition by ESS and ISS 
elements is carried out by the heterogeneous nuclear ribonucleoprotein protein 
(hnRNP) protein family. Similar to SR proteins, hnRNPs direct their influence on pre-
mRNA splicing through site-specific binding mediated by a RRM, with the exception of 
hnRNPs E/K, which interact with RNA via the K homology (KH) domain. Most hnRNPs 
also harbor auxiliary Arginine-Glycine-Glycine (RGG) boxes and glycine-patch domains 
that are often involved in protein–protein interactions (Busch & Hertel, 2012; 
Chaudhury et al., 2010; De Conti et al., 2013; Jensen et al., 2009). Although much 
remains to be learned about how these factors function, they can repress splicing 
either by sterical hindrance or by promoting the formation of inhibitory RNA secondary 
structures (De Conti et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Schematic diagram of key pre-mRNA splicing regulatory elements. Splice site choice is regulated not only 
by the core cis-sequence elements (5’ and 3’ ss) and associated 3’ sequences (polypyrimidine tract, Py; and branch 
point sequence, A) but also by additional enhancer and silencer elements in exons and introns (ESE/ESS: exonic 
splicing enhancers/silencers; ISE/ISS: intronic splicing enhancers/silencers) and by two main families of trans-acting 
splicing factors, Ser/Arg-rich proteins (SRs) and heterogeneous nuclear ribonucleoproteins (hnRNPs). These regulatory 
proteins as other trans-acting factors bind to enhancers and silencers and interact with spliceosomal components 
(shown in green) that associate with both the 5’ and the 3’ ss flanking the alternative exon and can have either 
activating (yellow arrow) or inhibitory (blue arrow) effects on the recognition and use of that site. Based in(Jensen et al., 
2009; McManus & Graveley, 2011; Wang & Burge, 2008) 
 
Frequently, the binding of SR proteins to enhancer motifs and hnRNPs to silencer 
elements promote the inclusion or exclusion of an exon, respectively. However, it 
Splice silencing 
Splice enhancing 
SR hnRNP Trans-acting splicing factor 
Exon Intron Intron 3’ ss 5’ ss 
hnRNP U2AF U2 U1 SR 
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should be noted that the same sequence motif can act as an enhancer or as a silencer, 
depending on its position with respect to the splice sites (Hartmann et al., 2008; Zhou & 
Fu, 2013). The activities of cis-acting elements were shown to be context-specific and 
there is compelling evidence that SR proteins (e.g. SRSF1, SRSF2, SRSF7) can 
suppress splicing when bound to sequences located within the intron. There are also 
examples of members of the hnRNPs (e.g. hnRNP F/H, TIA-1) exhibiting stimulating 
effects on splicing (Dauksaite & Akusjärvi, 2002; Dembowski et al., 2012; Erkelenz et 
al., 2013; Schaub et al., 2007). Additionally, the overall affinity, frequency and 
concentration ratio of the different protein family members can also influence the final 
decision of whether an exon is constitutively or alternatively included in the mature 
mRNA transcript (Busch & Hertel, 2012; Chen & Manley, 2009; Jensen et al., 2009). 
Globally, the sum of SRs and hnRNPs activities to enhance or repress cis-acting 
elements contributes to the overall recognition of an exon or to the overall binding 
affinity for the spliceosome.  
In the post-genomic era, research into the mechanisms of splice site selection is 
leading toward the establishment of rules that will allow splice patterns to be predicted 
on the basis of sequence information. Computational methods combined with 
laboratory experiments have already generated algorithm programs that predict 
sequence motifs of SREs (Hertel, 2008; Wang & Burge, 2008) as for example 
ESEfinder, available at http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process= 
home (Cartegni et al., 2003), ESRsearch, available at http://ibis.tau.ac.il/ssat/ESR.htm 
(Goren et al., 2006) and RESCUE-ESE, available at http://genes.mit.edu/burge 
lab/rescue-ese/ (Fairbrother et al., 2002; Yeo et al., 2004). These programs are useful 
tools that help to predict specific cis-acting elements and the respective trans-acting 
binding proteins in particular genes. However, they still often fail to identify these 
elements accurately and to make exact predictions of the effect of a given genomic 
mutation on the splicing process. Therefore, experimental analysis should be always 
considered to validate “dry-lab” predictions.  
 
The relative contributions of each of these factors, account to control how 
efficiently splice sites are recognised and flanking introns are removed. Therefore, the 
splicing process can be viewed as a series of checkpoints that allow the spliceosome 
to “examine” different choices and to adjust splicing decisions according to local 
dictates and cellular requirements. Such flexibility and control ultimately provide for the 
extent of alternative splicing that is now recognised to be pervasive in higher 
eukaryotes and essential for the functional diversity required in complex organisms 
(Hertel, 2008; House & Lynch, 2008). 
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1.1.3 Alternative splicing: from one gene to many proteins 
In humans, a myriad of proteins is needed to guarantee cellular functionality. This 
repertoire of different proteins can be largely explained by the occurrence of AS, a 
crucial mechanism for gene regulation that allows the production of several structurally 
and functionally different proteins from a single gene (Chen et al., 2012; Nilsen & 
Graveley, 2010). With the progressive generation of deep sequencing methodologies, it 
has been estimated that up to 95% of human multi-exon genes undergo AS (Pan et al., 
2008; Wang et al., 2008), leading to an estimated 90,000 protein species in humans, 
despite there being only roughly 25,000 genes (Consortium, 2004; Kim et al., 2007). 
Because many AS events occur in translated regions of mRNAs, they can affect the 
sequence of the encoded proteins. Therefore, changes in the primary structure can 
impact several aspects of protein biological function and properties such as subcellular 
localization, stability/expression, enzymatic activity, molecular interactions, binding 
properties and posttranslational modifications. Consequently, AS seems to be a major 
factor in coordinating physiologically meaningful changes in protein isoform expression 
and is a key mechanism to generate the complex proteome of multicellular organisms 
(Kelemen et al., 2013; Stamm et al., 2005). 
The potential to generate variability is enormous. Not only the majority of genes 
encode pre-mRNAs that are alternatively spliced but also the number of mRNA 
isoforms encoded by a single gene can vary from two to several thousands. For 
instance, the human neurexin-3 (NRXN3) gene can potentially form 1728 transcripts 
due to AS at four different sites (Tabuchi & Südhof, 2002) and in Drosophila, the Down 
syndrome cell adhesion molecule (Dscam) gene can potentially generate 38 016 
distinct mRNA isoforms, a number far in excess of the total number of genes (~14,500) 
in the organism (Schmucker et al., 2000). The significance of AS extends beyond the 
ability to generate different protein isoforms to the ability to modulate the levels of those 
isoforms. The proportions of different splice forms produced by AS may vary in different 
cell contexts, such as by cell or tissue type, developmental stage, gender, apoptosis, 
disease state or in response to external stimuli (Kelemen et al., 2013; Pajares et al., 
2007; Stamm et al., 2005).  
AS can be regulated at different steps of spliceosome assembly by different 
splicing factors and by many mechanisms that rely on cis-acting elements (Chen & 
Manley, 2009; House & Lynch, 2008). Correct AS also depends on the stoichiometry 
and interactions of positive and negative regulatory proteins (SR and hnRNPs). 
Therefore, differences in the activities or amounts of general splicing factors and/or 
gene-specific splicing regulators during development or in different tissues can cause 
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the differential patterns of splicing observed between different cell types (Chen & 
Manley, 2009; Cáceres & Kornblihtt, 2002; Hertel, 2008; Kalsotra & Cooper, 2011). The 
production of several isoforms from the same transcription unit by various types of AS 
(Figure 1.3) is a very common event in mammalian cells, and makes the already 
formidable task of correctly identifying splice sites even more complex (Cartegni et al., 
2002). Currently, there are several different types of AS events, which can be classified 
into four main subgroups. The first type is exon skipping, in which a type of exon known 
as a cassette exon is spliced out of the transcript together with its flanking introns 
(Figure 1.3A). The second and third types are alternative 5’ ss and 3’ ss selection. 
These types of AS events occur when two or more splice sites are recognised at one 
end of an exon (Figure 1.3B and 1.3C). The fourth type is intron retention, whereby an 
intron is retained in the resultant mature transcript (Figure 1.3D). Other classes of more 
complex events that give rise to alternative transcript variants include mutually 
exclusive exons (Figure 1.3E), alternative promoter usage (Figure 1.3F) and alternative 
polyadenylation sites (Figure 1.3G) (Chen et al., 2012; Gamazon & Stranger, 2014; 
Keren et al., 2010; Roy et al., 2013). Prevalence of each type of AS has been found to 
vary between different taxa. Several studies have shown that exon skipping is common 
in metazoan genomes (Alekseyenko et al., 2007; Kim et al., 2007; Sugnet et al., 2004) 
whereas intron retention is the most common type of AS among plants (Wang & 
Brendel, 2006) and fungi (Kim et al., 2008). 
Globally, the flexibility of AS contributes not only to expand protein diversity but 
also to the clockwork functioning of human biology. 
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Figure 1.3: Representation of the major forms of alternative splicing. Through alternative use of exons, introns, 
promoters and polyadenylation sites, alternative splicing acts to greatly increase the diversity of mRNA transcripts. A) 
Cassette exon or exon skipping; B) Alternative 5’ ss; C) Alternative 3’ ss; D) Intron retention; E) Mutually exclusive 
exons; F) Alternative promoters; G) Alternative poly-A sites. Adapted from(Li et al., 2007) 
 
1.1.4 Splicing and disease 
Given the widespread functions of splicing, it is not surprising that mutations in 
either alternatively or constitutively spliced genes can trigger aberrant splicing, which 
can lead to human disease (Douglas & Wood, 2011; Kelemen et al., 2013).  
Splicing defects constitute approximately 9% of all human pathogenic mutations 
(HGMD®Professional Release 2015.3) according to an estimate based on mutations at 
highly conserved splice sites. However, a growing understanding of cis splicing codes 
at locations other than splice sites has suggested that more than 50-60% of mutations 
that cause disease do so by disrupting splicing (Douglas & Wood, 2011; 
Lewandowska, 2013; López-Bigas et al., 2005).  
Alterations in splicing can cause disease directly, modify the severity of the 
disease phenotype or be linked with disease susceptibility. In each case, the 
mechanisms causing altered splicing involve disruption of either cis-acting elements 
within the affected gene or trans-acting factors that are required for splicing regulation. 
Disruption of cis-acting sequence elements have a direct impact on the expression of 
only one gene, whereas alterations in trans-acting factors such as a component of the 
splicing machinery or a splicing regulator might affect the expression of multiple genes 
(Kornblihtt et al., 2013; Wang & Cooper, 2007; Ward & Cooper, 2010). Most of the 
known splicing mutations occur mainly in the canonical nucleotides GT and AG at the 
5’ and 3’ ss, respectively, but can also disrupt other conserved splicing signals at the 
exon-intron junctions like the branch point and polypyrimidine tract sequences, and 
also auxiliary exonic or intronic splicing regulatory elements (Cartegni et al., 2002; 
Havens et al., 2013; Lewandowska, 2013; Tazi et al., 2005). The presence of such 
mutations can have different outcomes such as the complete or partial skipping of an 
exon, intron retention, introduction of a new splice site within an exon or intron or the 
activation of cryptic splice sites (Havens et al., 2013; Jensen et al., 2009). Mutations 
occurring deep within introns can also create or activate novel donor and acceptor 
F G 
Alternative promoters Alternative poly-A sites 
Poly-A 
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splice sites resulting in the inappropriate inclusion of intronic sequences, usually known 
as pseudoexons (Dhir & Buratti, 2010). In general, the use of unnatural splice sites or 
intron retention can origin non-functional proteins through the generation of out-of-
frame transcripts which can lead to premature termination codons (PTCs) into the 
mRNA, typically resulting in degradation of the transcripts by nonsense-mediated 
mRNA decay (NMD) and loss of function of the mutated allele (Faustino & Cooper, 
2003; Jensen et al., 2009). 
The pathogenicity of exonic mutations is generally assumed to result from the 
predicted effect on the reading frame and protein function. However, it is likely that the 
primary pathogenic effect for many exonic mutations is at the level of splicing (Havens 
et al., 2013; Wang & Cooper, 2007). For example, a single nucleotide change that does 
not change the encoded amino acid of a protein (a synonymous or silent mutation) 
might be misclassified as a neutral polymorphism when in fact it causes disruption of a 
crucial ESE and is a disease-causing mutation. Similarly, base changes that would 
result in premature stop codons (that is, nonsense mutations) or in amino acid changes 
(that is, missense mutations) might not only be acting at the level of the encoded 
protein but also at the pre-mRNA level by affecting the fate of splicing events 
(Kornblihtt et al., 2013). Therefore, to better understand the impact of every mutation at 
mRNA level, the study of splicing patterns by cDNA analysis and/or by functional 
assays using minigenes as a splicing model system is often necessary (Baralle & 
Baralle, 2005; Cáceres & Kornblihtt, 2002). Minigenes are splice reporter vectors (also 
known as exon-trapping vectors) which consist of exonic portions of a gene with 
functional 5’ and 3’ ss separated by an intronic sequence where a polylinker (i.e. a 
multiple cloning site into which a fragment of sample DNA can be inserted) is located. 
Any genomic region of interest, for example, an exon with part of its intronic flanking 
regions, can be amplified from normal or affected individuals and cloned into the 
minigene. The resultant constructs are then transiently transfected into an appropriate 
cell line and the vector splicing patterns are analysed allowing to disclose or confirm 
the mutations’ effect on the splicing process (Baralle et al., 2009; Desviat et al., 2012). 
In the last decade, minigenes have been widely used as a model system to study 
splicing mutations in several diseases as Spinal muscular atrophy (SMN1 and SMN2 
genes) (Cartegni et al., 2006), Familial adenomatous polyposis (APC gene) (Gonçalves 
et al., 2009), Congenital disorder of glycosylation type IA (PMM2 gene) (Vega et al., 
2009) and Duchenne muscular dystrophy (DMD gene) (Disset et al., 2006), having 
often allowed to identify the cis and trans-acting elements involved in the disease 
mechanism, thus adding to the understanding of the observed pathogenic splicing 
alterations. In general, the use of minigene vectors for splicing assays is essential not 
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only for diagnostic purposes but also for unravelling novel splicing regulatory 
mechanisms and monitor therapeutic interventions aimed at modulating splicing or at 
correcting splicing defects (Desviat et al., 2012).  
 
1.2 Lysosomal Storage Disorders: a brief overview 
and the burden of splicing mutations 
Lysosomes are membrane-enclosed compartments within the cytosol of most cell 
types, involved in the degradation of certain lipids, sugars, proteins, and nucleic acids, 
as well as foreign substrates, such as substances and pathogens, which enter cells 
from the extracellular milieu. This function is enabled by acidic hydrolytic enzymes 
working in concert with small activator molecules within the lysosomal lumen. Also 
important for lysosomal function are transport proteins and ion pumps in the lysosomal 
membrane, which maintain a harsh acidic environment in this organelle (Sabatini & 
Adesnik, 2001). Inherited deficiency of any component of the lysosomal system leads 
to a group of rare diseases designated Lysosomal Storage Disorders (LSDs). LSDs are 
a large group of more than 50 different Inherited Metabolic Diseases (IMDs) which, in 
the great majority of cases, result from the defective function of specific lysosomal 
enzymes and, in few cases, from defects in lysosomal membrane proteins, non-
enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal 
biogenesis and vesicular traffic (Boustany, 2013; Filocamo & Morrone, 2011). The 
biochemical hallmark of these diseases is the accumulation of undegraded metabolites 
in the lysosome. This accumulation results in generalized cell and tissue dysfunction 
which can cause a chain of secondary disruptions to other biochemical and cellular 
functions, leading to multi-systemic pathology (Filocamo & Morrone, 2011; Parkinson-
Lawrence et al., 2010; Platt et al., 2012). Storage may begin during early embryonic 
development, and the clinical presentation for LSDs can vary from an early and severe 
phenotype with rapid progressive neurological manifestations to late-onset mild 
disease (Filocamo & Morrone, 2011; Hopwood, 2012). LSDs can affect all systems of 
the body, with potential consequences in the skeleton and major organs, as well as the 
blood-forming and immune systems. Most of the diseases also affect the brain (Cox, 
2012). 
LSDs can be grouped according to various classifications. While, initially, they 
were classified according to the nature of the accumulated substrate(s), the more 
recent trend is to classify them on the basis of the molecular defect. Some LSDs are 
still referred to by the early class defined by the storage products as is the case of the 
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group of Mucopolysaccharidoses (MPSs) (accumulation of glycosaminoglycans also 
called mucopolysaccharides), Sphingolipidoses (storage of sphingolipids), 
Oligosaccharidoses also known as Glycoproteinoses (mostly characterized by the 
accumulation of oligosaccharides) and so on (Boustany, 2013; Filocamo & Morrone, 
2011; Winchester, 2012). However, some other lysosomal disorders did not fitted easily 
into this classification scheme and only the elucidation of their molecular basis has 
permitted a new classification based on the nature of the molecular defect in the 
lysosomal system, which includes groups of disorders due to: (i) non-enzymatic 
lysosomal protein defects; (ii) integral membrane protein defects (transporters and 
structural proteins); (iii) lysosomal enzyme protection defects; (iv) post-translational 
processing defects of lysosomal enzymes; (v) trafficking defects in lysosomal enzymes; 
and (vi) polypeptide degradation defects. There is also another group that includes the 
neuronal ceroid lipofuscinoses (NCLs), which are considered to be lysosomal 
disorders, even though distinct characteristics exist (Table 1.1) (Filocamo & Morrone, 
2011).  
 
Table 1.1: Classification of Lysosomal Storage Disorders 
Adapted from(Boustany, 2013; Filocamo & Morrone, 2011; Winchester, 2012) 
Disease Defective enzyme  
or protein 
Main storage 
materials 
Gene 
symbol 
Sphingolipidoses    
Fabry α-Galactosidase A Galactosylated glycolipids GLA 
Farber Acid ceramidase Ceramide ASAH1 
Gaucher  
(Types I, II and III) β-Glucosidase Glucosylceramide GBA 
Niemann-Pick 
(Types A and B) Sphingomyelinase Sphingomyelin SMPD1 
Sphingolipid-activator 
deficiency Sphingolipid activator  Glycolipids PSAP  
GM1 gangliosidosis  
(Types I, II and III) β-Galactosidase 
GM1 ganglioside, 
Keratan sulfate, oligos, 
glycolipids 
GLB1 
GM2 gangliosidosis  
(Tay-Sachs) β-Hexosaminidase A 
GM2 ganglioside, 
oligos, globoside, 
glycolipids 
HEXA 
GM2 gangliosidosis  
(Sandhoff) β-Hexosaminidase A and B 
GM2 ganglioside, 
oligos HEXB 
Krabbe disease 
(Globoid cell leukodystrophy) β-Galactosylceramidase Galactosylceramide GALC 
Metachromatic 
leukodystrophy Arylsulfatase A Sulfatides ARSA 
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Mucopolysaccharidoses (MPS) 
MPS I (Hurler, Scheie, 
Hurler/Scheie) α-L-Iduronidase 
Dermatan sulfate, 
heparan sulfate IDUA 
MPS II (Hunter) Iduronate-2-sulfatase Dermatan sulfate, heparan sulfate IDS 
MPS IIIA (Sanfilippo A) Heparan-N-sulfatase (sulfamidase) Heparan sulfate SGSH 
MPS IIIB (Sanfilippo B) N-Acetyl-α-glucosaminidase Heparan sulfate NAGLU 
MPS IIIC (Sanfilippo C) Acetyl-CoA:α-glucosaminide N-acetyltransferase Heparan sulfate HGSNAT 
MPS IIID (Sanfilippo D) N-Acetylglucosamine-6-
sulfatase Heparan sulfate GNS 
MPS IVA (Morquio A) N-Acetylgalactosamine-6-
sulfatase 
Keratan sulfate, 
chondroitin-6-sulfate GALNS 
MPS IVB (Morquio B) β-Galactosidase Keratan sulfate GLB1 
MPS VI (Maroteaux-Lamy) N-Acetylgalactosamine-4-
sulfatase (arylsulfatase B) Dermatan sulfate ARSB 
MPS VII (Sly) Β-Glucuronidase 
Dermatan sulfate, 
heparan sulfate, 
chondroitin-6-sulfate 
 
GUSB 
MPS IX (Natowicz) Hyaluronidase Hyaluronan HYAL1 
Oligosaccharidoses (Glycoproteinoses) 
Aspartylglicosaminuria Aspartylglucosaminidase (Glycosylasparaginase) Aspartylglucosamine AGA 
Fucosidosis α-L-Fucosidase 
Glycoproteins, 
glycolipids, Fucoside-
rich oligos 
FUCA1 
α-Mannosidosis α-D-Mannosidase Mannose-rich 
oligosaccharides MAN2B1 
β-Mannosidosis β-D-Mannosidase Man (β14) GlnNAc MANBA 
Sialidosis (Mucolipidosis I) Neuraminidase (Sialidase 1) Oligos, glycopeptides NEU1 
Schindler/Kanzaki α-N-Acetylgalactosaminidase Sialylated/asialoglyco-peptides, glycolipids NAGA 
Glycogenoses    
Pompe  
(Glycogenosis type II) α-1,4-glucosidase  Glycogen, oligos GAA 
Lipidoses    
Wolman, cholesterol ester 
storage disease (CESD) Acid lipase Cholesterol esters LIPA 
Non-enzymatic lysosomal protein defects 
GM2 gangliosidosis  
(GM2 activator deficiency) GM2 activator protein 
GM2 ganglioside, 
oligos GM2A 
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Metachromatic 
leukodystrophy Saposin B Sulfatides PSAP 
Krabbe disease, atypical Saposin A Galactosylceramide PSAP 
Gaucher, atypical Saposin C Glucosylceramide PSAP 
Integral membrane protein defects 
Transporters    
Cystinosis Cystinosin (cystine transporter) Cystine CTNS 
Sialic acid storage disease; 
infantile form (ISSD) and 
adult form (Salla) 
Sialin (sialic acid transporter) Sialic and uronic acids SLC17A5 
Niemann-Pick type C1 Niemann-Pick type C1 protein (proton-driven transporter) 
Cholesterol and 
sphingolipids NPC1 
Niemann-Pick type C2 Niemann-Pick type C2 protein (proton-driven transporter) 
Cholesterol and 
sphingolipids NPC2 
Structural proteins    
Danon disease Lysosome-associated 
membrane protein 2 (LAMP-2) 
Cytoplasmic debris and 
glycogen  LAMP2 
Mucolipidosis IV Mucolipin Lipids MCOLN1 
Lysosomal enzyme protection defects 
Galactosialidosis Protective protein cathepsin A (PPCA) 
Sialyloligosaccharides 
and glycopeptides CTSA 
Post-translational processing defects 
Multiple sulfatase deficiency Formylglycine generating 
enzyme (SUMF1) 
Sulfatides, GAGs, 
glycolipids SUMF1 
Trafficking defects in lysosomal enzymes 
Mucolipidosis II α/β  
(ML II or I-cell) 
Mucolipidosis III α/β  
(ML IIIA or pseudo-Hurler 
polydystrophy) 
N-acetylglucosamine-1-
phosphotransferase – α/β 
subunit 
Oligos, GAGs, lipids GNPTAB 
Mucolipidosis III γ  
(ML III variant) 
N-acetylglucosamine-1-
phosphotransferase – γ 
subunit 
Oligos, GAGs, lipids GNPTG 
Polypeptide degradation defects 
Pycnodysostosis Cathepsin K Collagen and other bone proteins CTSK 
Neuronal ceroid lipofuscinoses (NCLs) 
NCL 1 Palmitoyl protein thioesterase 1 (PPT1) 
Lipofuscin, Saposins A 
and D PPT1 
NCL 2 Tripeptidyl peptidase 1 (TPP1) Lipofuscin, Subunit c of ATP synthase TPP1 
NCL 3 CLN3, lysosomal and/or Golgi transmembrane protein 
Lipofuscin, Subunit c of 
ATP synthase CLN3 
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NCL 4 DnaJ homologue subfamily C 
member 5 
Lipofuscin, Subunit c of 
ATP synthase DNAJC5 
NCL 5 CLN5, soluble lysosomal protein 
Lipofuscin, Subunit c of 
ATP synthase CLN5 
NCL 6 CLN6, transmembrane protein in endoplasmic reticulum 
Lipofuscin, Subunit c of 
ATP synthase CLN6 
NCL 7 
CLN7/MFSD8 (major facilitator 
superfamily domain-containing 
protein 8), transporter 
Lipofuscin, Subunit c of 
ATP synthase MFSD8 
NCL 8 CLN8, transmembrane protein in endoplasmic reticulum 
Lipofuscin, Subunit c of 
ATP synthase CLN8 
NCL 10 Cathepsin D Lipofuscin, Saposins A 
and D CTSD 
NCL 11 Progranulin * GRN 
NCL 12 P type ATPase * ATP13A2 
NCL 13 Cathepsin F * CTSF 
NCL 14 
Potassium channel 
tetramerization domain-
containing protein 7 
* KCTD7 
*The underlying genes of these four (NCL 11 – 14) variants have already been identified; however, data on their associated storage 
materials is still scarce.  
 
The frequency of LSDs varies across populations and geographical regions. 
Although individually rare, the prevalence of LSDs is significant when the group is 
considered as a whole, varying from one case in every 4000 to 8000 births across 
different studies (Fuller et al., 2006; Meikle et al., 1999; Pinto et al., 2004; Poorthuis et 
al., 1999; Poupetová et al., 2010). Comparatively to other IMDs, the class of LSDs is 
relatively frequent in the Portuguese population, presenting a prevalence of 1:4000 live 
births (Pinto et al., 2004). 
Most LSDs are autosomal recessive diseases, with the exception of Hunter 
syndrome (MPS II) and Fabry disease which are X-linked recessive; Danon disease, 
which shows X-linked dominant inheritance and the Parry disease (a variant type of 
adult NCL4), which is autosomal dominant (Boustany, 2013; Hopwood, 2012). 
Although being monogenic diseases, for most LSDs, numerous mutations have been 
described for the same gene in different patients. These mutations include missense, 
nonsense and splice site mutations, partial deletions and insertions (Futerman & van 
Meer, 2004). In general, mutations resulting in null or very low residual enzyme activity 
cause the most severe early onset forms of the diseases. In contrast, higher residual 
enzyme activity delays disease onset. However, no obvious genotype–phenotype 
correlation has been found for most LSDs and prediction of the clinical course of the 
disease cannot usually be made only on the basis of mutational analysis (Futerman & 
van Meer, 2004; Hopwood, 2012). Different epigenetic factors, genetic variability in the 
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synthesis of the stored substrate, and the overall functional efficiency and control of an 
individual patient’s endosome-lysosome-network are other factors that may influence 
clinical outcome (Hopwood, 2012).  
As mentioned before, splicing mutations are only one of the underlying causes of 
LSDs, even though having been identified in many patients. Specifically for a group of 
well-known lysosomal diseases (Fabry, Gaucher, Pompe, Niemann-Pick type C, 
Gangliosidosis GM1 and GM2, MPSs and NCLs) splicing mutations account for ~9% of 
all described mutations (HGMD®Professional Release 2015.3). This figure may likely 
be an underestimate given that only genomic DNA analysis is routinely performed in 
the diagnostic setting, uncovering the real impact that many silent, missense and 
nonsense mutations may have on the splicing process.  
Great strides have been made in the characterization of biochemical and 
molecular basis of most LSDs, which naturally generated excitement and anticipation 
regarding direct approaches to therapy. However, despite the accumulated knowledge 
about disease mechanisms and much biopharmacological investment, for most LSDs, 
no curative therapy is available, although a number of specific treatment strategies do 
exist for some, aiming to improve quality of life (Boustany, 2013; Cox, 2012). 
Essentially, the primary aim of treatment is the preservation or restoration of organ 
function, which can be achieved by preventing or reducing tissue substrate build up. 
Clinically proven approaches include the restoration of intracellular activity through 
cross-correction, by transplanting healthy donor cells (bone marrow or umbilical cord 
blood as a source of haematopoietic stem cells) or infusion of the relevant exogenous 
enzyme (enzyme replacement therapy – ERT), and by substrate synthesis inhibition 
(substrate reduction therapy – SRT). Haematopoietic stem cells transplantation (HSCT) 
have the potential to supply complementing enzyme activity over the long-term and has 
led to good results in some cases (MPS I and VI; Metachromatic leukodystrophy; 
Krabbe disease and α-Mannosidosis), but only if the procedure is performed at an early 
phase of disease progression. Also, it is limited by the availability of compatible donors 
and by procedural complications with significant morbidity and mortality (Cox, 2012; 
Lachmann, 2010; Pastores, 2010). ERT on the other hand, uses recombinant versions 
of the deficient enzymes to overcome the cellular defect. This approach is only 
available for a restrict number of LSDs (Gaucher type I, Fabry, Pompe and MPS I, II, 
IVA and VI), even though it will probably be extended to others for which clinical trials 
are already in course (α-Mannosidosis, Wolman disease and Niemann-Pick type B). 
ERT has generally shown to be effective in treating systemic symptoms and slowing 
down the disease progression in later onset or milder variants of LSDs. Unfortunately, 
ERT cannot treat the neurological manifestations present in patients affected by the 
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more severe types of LSDs, given the inability of recombinant enzymes to cross the 
blood brain barrier (BBB) and reach the brain (Boustany, 2013; Cox, 2012; Cox, 2015). 
Concerning the SRT strategy, whose principle is to reduce the biosynthesis of new 
storage material, it is currently available for Gaucher disease and Niemann-Pick type 
C, and being evaluated for some other lysosomal disorders (MPS, Fabry, late onset 
GM2 Gangliosidosis and Sandhoff disease) (Cox, 2012; Cox, 2015; Pastores, 2010; 
Platt & Jeyakumar, 2008).The ineffectiveness of ERT and, in some cases of bone 
marrow transplantation (BMT) and SRT, to overcome neurological symptoms is one of 
the main reasons prompting research on additional therapeutic approaches to address 
the needs of the more severe types. Other strategies presently under study include 
pharmacological chaperones, gene therapy and stop-codon read-through technology 
(Boustany, 2013; Cox, 2015; Pastores, 2010; Tomanin et al., 2012). Still, if early 
diagnosis of these disorders before the onset of irreversible pathologies is already 
crucial to obtain better outcomes for current therapies, it certainly will continue to be for 
the innovate medicines that hopefully will appear in the next years. 
 
1.3 RNA-based therapies  
A strong conviction is being formed that as diagnostic approaches become 
individualized through whole genome sequencing as well as transcriptome and 
epigenetic profiling, the fraction of the detected disease-causing mutations and single 
nucleotide polymorphisms (SNPs) predisposing to disease or modulating disease 
severity that affect splicing will increase (Cooper et al., 2009; Singh & Cooper, 2012). 
The continuous discovery of new disease-causing mutations in RNAs is yielding a 
wealth of new therapeutic targets, and the growing understanding of RNA biology and 
chemistry is also providing new tools that can be exploited in the development of RNA-
based therapeutics (Cooper et al., 2009; Douglas & Wood, 2011; Singh & Cooper, 
2012). Concerning approaches to manipulate splicing for therapy, significant advances 
have been achieved by now. Splicing can be manipulated with a number of tools 
including antisense oligonucleotides (AOs), overexpression or silencing of specific 
splicing factors, modified U1 snRNAs, spliceosome-mediated RNA trans-splicing 
(SMaRT) and using small molecule compounds (e.g. pentamidine, sodium butyrate, 
kinetin and tetracycline derivatives), all of them applied to increase specific alternatively 
spliced isoforms or to correct aberrant gene expression resulting from gene mutations 
that alter splicing (Arechavala-Gomeza et al., 2014; Douglas & Wood, 2011; Havens et 
al., 2013; Pérez et al., 2012; Rigo et al., 2014; Wally et al., 2012). Since the AOs and 
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the modified U1 snRNA therapeutic approaches were the two options selected for this 
work, they will be the focus of the next sections.  
 
1.3.1 Antisense oligonucleotides technology 
Antisense oligonucleotide-based therapy covers a range of methods for 
modifying gene expression, which have the potential to revolutionize the development 
of therapeutics and biomedical practice (Magen & Hornstein, 2014). The modification of 
gene expression, using a synthetic single stranded DNA, resulting in inhibition of 
mRNA translation was demonstrated for the first time by Paterson and colleagues in 
1977 in a cell-free system (Paterson et al., 1977). Almost a year later, Zamecnik and 
Stephenson showed that in chicken fibroblast tissue culture containing Rous Sarcoma 
virus, the addition of a synthetic 13-mer oligonucleotide complementary to the 3’ end of 
the virus, could inhibit its replication and transformation of fibroblasts into sarcoma cells 
(Zamecnik & Stephenson, 1978). Since then, remarkable progress has been made in 
oligonucleotide drug development and currently antisense technology is a powerful tool 
that can be used for target validation and to correct or alter RNA expression for 
therapeutic benefit (Bennett & Swayze, 2010; Evers et al., 2015; Havens et al., 2013; 
Rigo et al., 2014).  
AOs are short, synthetic, and modified nucleic acids that are able to bind to 
mRNA or pre-mRNA with high specificity via base-pairing and to interfere in its function 
through a variety of post-binding events (Bennett & Swayze, 2010; Rigo et al., 2014). 
Depending on the chemistry and target site, AOs are able to perform their function 
through different mechanisms, being important to distinguish between those that 
knockdown gene expression by degrading the target RNA via enzymes such as RNase 
H, or Argonaute 2 (RNA interference), and those that act in splicing modulation without 
promoting RNA degradation as the splice switching oligonucleotides (SSOs). SSOs are 
single stranded AOs typically 15-25 nucleotides long which direct pre-mRNA splicing to 
a new pathway by binding sequence elements and sterically blocking access to the 
transcript by the spliceosome and other splicing factors (Bauman et al., 2009; Bennett 
& Swayze, 2010; Kole et al., 2012; Rigo et al., 2014). 
 
1.3.2 Antisense oligonucleotides chemistry  
To be suitable for therapeutic application, AOs ideally require a number of 
intrinsic properties. To start off with, the AO should bind in a sequence specific manner 
to the target RNA transcript; the higher the specificity, the less the chance of unwanted 
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off-target effects. Secondly, the AO should be of a chemistry that facilitates cellular 
uptake and activity in the appropriate intracellular compartment (e.g. nucleus or 
cytoplasm). Thirdly, because of the plethora of nucleases present in vivo, a well-
designed AO should be resistant to nuclease degradation in order to allow it to reach 
its desired target intact and to maximize its potential duration of action once there. 
Fourthly, as with any drug, the ideal AO should have favorable pharmacokinetics (PK) 
and pharmacodynamics (PD). Linked to this is, of course, the prerequisite that the AO 
should not be a toxic compound. Finally, the design of the AO must allow its effective 
delivery to the target tissues, whether that be a localized area such as a specific organ 
or a body-wide systemic delivery (Bennett & Swayze, 2010; Douglas & Wood, 2013; 
Geary et al., 2015; Mansoor & Melendez, 2008; Rigo et al., 2014). To try to cope with 
these desired AO properties, several chemical modifications have been made to the 
backbone and sugar component of AOs allowing the development of different 
oligonucleotide chemistries with features that make them potential therapeutic tools 
(Bennett & Swayze, 2010; Mansoor & Melendez, 2008; Rigo et al., 2014).  
 
1.3.2.1 ‘First generation oligonucleotides’: the PS backbone 
modification 
The precise positioning of chemical modifications within an AO fundamentally 
determines its mechanism of action. One of the first successful modifications, which 
remains widely used in antisense therapeutics, is the phosphorothioate (PS) backbone 
(Figure 1.4). Termed the first generation of oligonucleotide modifications, the PS 
backbone is accomplished by replacement of one of the non-bridging oxygen atoms of 
the natural phosphodiester linkage in the backbone with a sulfur atom. This simple 
chemical modification improves resistance to nucleolytic degradation, elicits RNase H-
mediated cleavage of the target mRNA, carries negative charges that facilitate their cell 
delivery in vitro an in vivo, and increases affinity for plasma proteins leading to reduced 
renal clearance and an increased circulation time of the AO (Bennett & Swayze, 2010; 
Evers et al., 2015; Kurreck, 2003; Mansoor & Melendez, 2008; Rigo et al., 2014). 
However, the binding of PS AOs not restrictively to serum proteins can also be a 
disadvantage due to the production of undesirable side effects such as nonspecific 
activation of the immune system (Evers et al., 2015; Rigo et al., 2014). The first AO 
drug approved for clinical use, the intravitreous Fomivirsen® (Vitravene) was a first 
generation PS-modified oligonucleotide used for repression of cytomegalovirus mRNA 
translation. It gained United States Food and Drug Administration (U.S. FDA) approval 
for intraocular treatment of Cytomegalovirus retinitis in immunosuppressed patients in 
FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
51 
 
1998 (Roehr, 1998) and was discontinued later due to commercial considerations 
(Magen & Hornstein, 2014).  
 
 
Figure 1.4: Antisense oligonucleotides chemical structures. Schematic representation of unmodified DNA/RNA base 
pair (left). Different backbone modifications that can be applied (top row) and different 2’-sugar modifications that can be 
used (bottom row) to increase nuclease resistance and RNA binding affinity of the antisense oligonucleotide. Deviations 
from the original unmodified DNA/RNA are highlighted by circles. Adapted from(DeVos & Miller, 2013)  
 
1.3.2.2 ‘Second generation oligonucleotides’: the sugar group 
modifications 
Another class of oligonucleotide modifications includes those made at the 2’ 
position of the sugar ring, which in combination with the PS backbone has highly 
improved oligonucleotide safety and pharmacologic properties. The class represents 
the second generation of oligonucleotides, whose most successful members are the 2’-
O-methyl (2’-OMe) and 2’-O-methoxyethyl (2’-MOE) modifications (Figure 1.4). They 
have improved the PS backbone oligonucleotides, with enhancements in nuclease 
resistance and RNA-binding affinity, better tissue uptake, longer in vivo half-life and 
reduction of nonspecific protein binding, which in turn, contributed to reduce the AO 
toxicity profile (Bennett & Swayze, 2010; Chan et al., 2006; Evers et al., 2015; Kurreck, 
2003; Mansoor & Melendez, 2008).   
These desirable properties are, however, counterbalanced by the fact that 2’-O-
alkyl fully modified oligonucleotides cannot induce RNase H cleavage of a target RNA 
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(RNase H requires a free 2′-oxygen), which restricts the use of 2’ modifications for 
antisense downregulation purposes (Bennett & Swayze, 2010; Evers et al., 2015; 
Kurreck, 2003). This limitation has been minimized with the development of “gapmer” 
structures where 2’ sugar-modified residues are present on either side of a central 
“gap” region comprising 8-10 PS-modified nucleotides. The external sugar modified 
residues thus increase affinity and nuclease resistance, while the internal “gap” region 
allows RNase H-mediated cleavage of the target RNA (Bennett & Swayze, 2010; Kole 
et al., 2012; Monia et al., 1993; Rigo et al., 2014). 
Recently, a systemically administered AO of the 2’-MOE gapmer type - 
Kynamro®, which targets apolipoprotein B (APOB) transcripts, was approved by the 
U.S. FDA for the treatment of Familial hypercholesterolemia (Crooke & Geary, 2013). 
Also, the phase I clinical trials were recently concluded for another 2’-MOE gapmer 
oligonucleotide (ISIS-333611) targeting the exon 1 of SOD1 gene mutated in 
Amyotrophic lateral sclerosis (ALS) disease (Miller et al., 2013). 
 
1.3.2.3 ‘Second and third generation oligonucleotides’: 
designing AOs for splicing modulation 
For splicing modulation, oligonucleotides were developed that do not induce 
RNase H-mediated cleavage of RNA but instead act by blocking a specific site in the 
targeted RNA without inducing its degradation. The most commonly used splice-
switching oligonucleotide chemistries include the second generation PS-modified 2’-
OMe and 2'-MOE AOs and also the phosphorodiamidate morpholino oligomer (PMO) 
and locked nucleic acid (LNA) designs which are part of a third generation class of AOs 
(Figure 1.4) (Aartsma-Rus & van Ommen, 2007; Bauman et al., 2009; DeVos & Miller, 
2013; Rigo et al., 2014). This third class was developed mainly by chemical 
modifications of the furanose ring of the nucleotide, along with modifications of 
phosphate linkages aiming to further enhance nuclease stability, target affinity, 
pharmacokinetic and toxicology profiles of the AOs (Chan et al., 2006; Evers et al., 
2015; Mansoor & Melendez, 2008). 
The PMOs represent a successful modification in which the ribose sugar is 
replaced by a six-membered morpholine ring and the negatively charged 
phosphodiester backbone is replaced with a neutral phosphorodiamidate backbone 
(Figure 1.4) (Summerton & Weller, 1993; Summerton, 2007). Morpholinos are usually 
constituted by a 25 nucleotide chain which presents high target specificity and affinity, 
good solubility in aqueous solution, high resistance to nucleases and do not activate 
RNase H, being used primarily in splicing modulation and translational interference 
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through steric hindrance of the ribosomal machinery (Bennett & Swayze, 2010; 
Summerton, 1999; Summerton, 2007).  
Unlike PS oligonucleotides, PMOs have no net electrical charge and, therefore, 
do not tend to interact with nucleic acid-binding proteins. On the one hand, this reduces 
the chance of side effects, but on the other hand, poor protein binding causes the drug 
to be rapidly cleared from the body and high doses of the oligonucleotide are required 
to elicit a pharmacological response (Mansoor & Melendez, 2008; Rigo et al., 2014). 
Also, their electrostatically neutral backbones at physiological pH make difficult the 
cellular uptake. For this reason their delivery into tissue cell culture can be improved by 
non-toxic endocytosis-assisted delivery reagents like ethoxylated polyethylenimine 
(EPEI) (Morcos, 2001) and Endo-Porter® (Summerton, 2005) as also by the scrape 
delivery method (Partridge et al., 1996). As expected, these antisense molecules also 
do not readily cross cell membranes in vivo without delivery techniques. To overcome 
this problem, another chemical modification was made to allow the oligonucleotides to 
more easily penetrate cell membranes and to improve their PK properties (Evers et al., 
2015; Lee & Yokota, 2013; Moulton & Jiang, 2009). The first effective chemically-
mediated method for systemic delivery of morpholino antisense was based on 
covalently linking the oligonucleotides to arginine-rich (arg-rich) cell-penetrating 
peptides (CPPs), resulting in the peptide-linked phosphorodiamidate morpholino 
oligomers, or PPMO (Figure 1.5A) (Moulton et al., 2003). The presence of positively 
charged guanidinium moieties as part of the arginine chains in this conjugated 
oligonucleotides is responsible for its increased cellular uptake (Moulton & Moulton, 
2004; Wender et al., 2000).  
Another interesting conjugated PMO, which exhibits superior performance in 
transporting morpholino oligomers across biological barriers is the vivo-morpholino 
(vPMO) (Figure 1.5B). vPMOs are morpholino oligonucleotides covalently linked to a 
dendrimer scaffold which carries eight guanidinium head groups that enable delivery 
into cells (Li & Morcos, 2008; Morcos et al., 2008). This molecular transporter showed 
efficient delivery of coupled morpholino oligomers to a wide spectrum of tissues without 
evidence of toxicity after its intravenous injection in transgenic mice (Morcos et al., 
2008) and in a dystrophic mdx mouse model (Aoki et al., 2012). However, other recent 
studies targeting the SMN2 (Zhou et al., 2013) and PAH (Gallego-Villar et al., 2014) 
genes have reported severe toxicity after the systemic administration of v-PMOs in 
mice, even though an effective splicing modulation has also been observed. 
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Figure 1.5: Chemical structure of a peptide-linked phosphorodiamidate morpholino (PPMO) and a vivo-morpholino 
(vPMO). A) Representation of the PMO subunits linked to the arginine-rich peptide in the PPMO structure. R – arginine; 
X – 6-aminohexanoic acid, B – β-alanine; Base – A, C, G or T. B) Representation of a v-PMO structure. Shown are two 
3′ end PMO subunits (top portion) linked to the molecular transporter with eight guanidinium head groups (bottom 
portion). B – base. Adapted from(Goyenvalle & Davies, 2011; Morcos et al., 2008) 
 
LNA oligonucleotides constitute a class of chemically modified RNA nucleotides 
that has been also widely used seeking therapeutic applications. LNAs contain a 
methylene bridge connecting the 2’-O with the 4’-C position in the furanose ring, which 
enables it to form a strictly N-type conformation that offers to the nucleic acid an 
unprecedented binding affinity and excellent specificity toward complementary RNA or 
DNA (Figure 1.4) (Obika et al., 1997; Singh et al., 1998; Vester & Wengel, 2004). LNAs 
show structural resemblance with RNA, high resistance to nucleolytic degradation with 
consequent high bio-stability, good aqueous solubility, great thermal stability of the 
duplexes and are easy to synthesize (Kaur et al., 2007; Veedu & Wengel, 2009; Vester 
& Wengel, 2004). Furthermore, the charged phosphate backbone of LNAs allows their 
ready delivery into cells using standard cationic transfection agents (Kaur et al., 2007). 
The high RNA binding affinity and potency of LNAs was demonstrated in vivo 
without evidence of toxicity after systemic administration in mice (Gupta et al., 2010; 
Roberts et al., 2006) or when applied directly in rat brain (Wahlestedt et al., 2000). 
However, profound levels of hepatotoxicity were reported in mice after intraperitoneal 
delivery (Swayze et al., 2007). As interestingly revealed in a recent work of Burdick and 
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colleagues (2014), the hepatotoxicity observed after LNA administration in mice seems 
to be strongly associated with the presence of specific trinucleotide sequence motifs in 
the oligonucleotide. AOs containing these sequence motifs tend to exhibit higher 
binding to mouse liver proteins, which results in the activation of transcription factors 
that trigger specific stress pathways leading to hepatotoxicity. This finding suggests 
that in silico approaches can be used to evaluate structure–toxicity relationships of 
LNA-modified AOs aimed at decreasing the likelihood of hepatotoxicity in preclinical 
testing (Burdick et al., 2014). 
 
1.3.3 Factors influencing antisense oligonucleotides activity 
All antisense mechanisms have in common the binding of the oligonucleotide to 
the targeted RNA. What happens after the oligonucleotide binding is dictated not only 
by the oligonucleotide chemistry but also by additional factors that may influence its 
activity. Among them are the oligonucleotide length, the melting temperature (Tm), the 
guanine-cytosine content, the presence of secondary or tertiary structures formed by 
RNA that can compromise the accessibility of the AO to the target, or sequence motifs 
for the binding of auxiliary factors like RNA-binding proteins, as well as the local in the 
cell (nucleus or cytoplasm) where the AO binds to the RNA. To design an AO all these 
aspects should be taken into account and every option should firstly be screened for 
activity in cell culture. This step is essential to find the most effective oligonucleotide(s) 
for a particular antisense mechanism, which can subsequently be tested in vivo 
(Aartsma-Rus, 2012; Aartsma-Rus et al., 2009; Rigo et al., 2014).  
 
1.3.4 The use of antisense oligonucleotides for splicing 
modulation 
The ultimate goal in the development of many AO-based therapies is to block the 
production of a toxic form of a protein or to restore i) the production of a protein that is 
not translated, or ii) the activity of a nonfunctional protein. For this, SSOs are designed 
to base-pair to pre-mRNA, in order to influence splicing through the alteration of the 
protein-coding mRNA (Havens et al., 2013). The first demonstration of the ability of a 
SSO to correct a splicing mutation appeared two decades ago for the β-globin gene, 
where SSOs were successfully used to mask the activated intronic cryptic splice sites 
leading to abnormal splicing and causing β-thalassemia (Dominski & Kole, 1993). 
Since then, SSOs have been fruitfully employed in numerous applications targeting 
many disease-relevant genes including a number coding for IMDs (Arechavala-
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Gomeza et al., 2014; Bauman & Kole, 2011; Lee & Yokota, 2013; Pérez et al., 2010; 
Pérez et al., 2012; Siva et al., 2014; Veltrop & Aartsma-Rus, 2014). 
Splicing modulation can be achieved through different approaches depending on 
the nature of the mutation to correct. For instance, SSOs can be used to block cryptic, 
new, or pseudo splice sites in the pre-mRNA (Figure 1.6A), as was already done to 
efficiently neutralize aberrant splice sites in cells of patients with Ataxia-telangiectasia 
(Du et al., 2007; Nakamura et al., 2012), Pyridoxine-dependent epilepsy (Pérez et al., 
2013), Hypomyelinating leukodystrophy (Regis et al., 2013), Congenital disorders of 
glycosylation (Vega et al., 2009; Yuste-Checa et al., 2015) and Niemann-Pick C 
disease (Rodríguez-Pascau et al., 2009) or in animal models of Hutchinson-Gilford 
progeria syndrome (Osorio et al., 2011) and Usher syndrome (Lentz et al., 2013). 
SSOs can also be used to promote the inclusion of an exon by targeting splicing 
regulatory sequences (Figure 1.6B). A case of success is illustrated by Spinal muscular 
atrophy (SMA), the leading genetic cause of mortality in infants under the age of 2 
years, in which SSOs were used to block an ISS promoting exon inclusion (Hua et al., 
2010; Hua et al., 2008). For this disease, SSOs antisense therapy is now in phase II 
clinical trials (ISIS-SMNRx; 2’-MOE; ClinicalTrials.gov), showing potential to become a 
treatment for SMA patients (Rigo et al., 2012; Zanetta et al., 2014). Another approach 
is based on the use of SSOs to remove exons either to eliminate a nonsense mutation 
or to restore the reading frame around a genomic deletion (Figure 1.6C). It was the 
strategy applied in Duchenne muscular dystrophy, an early onset, severe 
neuromuscular disorder caused in the majority of patients by deletions or duplications 
of one or more exons that result in disruption of the open reading frame (ORF) and 
deficit of its encoded protein, dystrophin (Muntoni et al., 2003). In a model of “exon 
skipping”, SSOs were used to “mask” specific exons to the splicing machinery, 
restoring the ORF with consequent production of internally deleted but partially 
functional proteins for DMD patients. The developments in the use of SSOs as a 
potential therapeutic agent in DMD have been fast since the early proof of concept 
experiments (Alter et al., 2006; Lu et al., 2003; van Deutekom et al., 2001; Yokota et 
al., 2009) to the phase II (Eteplirsen (AVI-4658); PMO; targeting exon 51) and III 
(Drisapersen; 2’-OMe; targeting exons 51, 44, 45 and 53) clinical trials that are 
currently underway revealing encouraging results (Aartsma-Rus, 2014; Cirak et al., 
2011; Goemans et al., 2011; Mendell et al., 2013). However, AO-mediated exon-
skipping for DMD still faces major hurdles such as extremely low efficacy in the cardiac 
muscle, no crossing of the BBB, poor cellular uptake and relatively rapid clearance 
from circulation. Therefore, to overcome these limitations new modifications and 
chemistries are being explored in pre-clinical tests, including for dystrophin exon 
FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
57 
 
skipping. One such example is the recent study of Betts and colleagues (2012), where 
the development of novel Pip (PMO internalization peptide) transduction peptides, 
termed Pip6-PMOs, led in a DMD mouse model to efficient exon skipping and 
dystrophin restoration in multiple muscle groups (Betts et al., 2012). In another study, 
Goyenvalle and co-workers (2015) used a new class of conformationally constrained 
DNA analogues: the tricyclo-DNAs (tc-DNAs), which displayed unprecedented uptake 
after systemic administration and induced efficient exon skipping in a DMD mouse, 
promoting a high degree of dystrophin rescue in several tissues including the brain 
(Goyenvalle et al., 2015). This makes tc-DNA AO chemistry particularly attractive as a 
potential future therapy for patients with DMD or with other diseases that are eligible for 
exon-skipping approaches requiring whole-body treatment. The exon-skipping process 
of splicing modulation was also applied with success in cells from patients suffering 
from dysferlinopathies (Aartsma-Rus et al., 2010; Wein et al., 2010). SSOs can also be 
applied to manipulate alternative splicing from one splice variant to another (Figure 
1.6D) as was demonstrated in Fronto-temporal dementia and Parkinsonism linked to 
chromosome 17 (FTDP-17) (Kalbfuss et al., 2001; Peacey et al., 2012), in some 
cancers (Bauman et al., 2010; Wan et al., 2009; Zammarchi et al., 2011), and in 
inflammatory disorders (Graziewicz et al., 2008; Vickers et al., 2006).  
In addition to splicing modulation, AOs have been used to disrupt interactions 
between a protein splicing factor and a toxic repeat-containing RNA in myotonic 
dystrophy (Leger et al., 2013; Wheeler et al., 2009), to inhibit translation in Huntington, 
Machado Joseph (Evers et al., 2011; Gagnon et al., 2010; Hu et al., 2009) and 
Alzheimer (Erickson et al., 2012; Kumar et al., 2000) diseases as well as to inhibit the 
viability of bacteria (Geller et al., 2005) and virus (Warren et al., 2010). AOs of the 
PMO class have been extensively used in studies of gene function and development in 
a variety of organisms like frog, zebrafish, chicken, mouse and sea urchin (Eisen & 
Smith, 2008; Ferguson et al., 2013) as in the generation of disease models, mainly in 
mouse and zebrafish (Cline et al., 2012; Gallego-Villar et al., 2014; Mahmood et al., 
2013; Moro et al., 2010).  
 
A) Cryptic and Pseudo splice sites 
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B) Exon inclusion 
 
 
 
 
 
 
 
C) Exon exclusion 
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D) Alternative splicing  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Methods of AO-mediated modification of mutation-generated aberrant splicing. AOs have been used to 
revert aberrant splicing of activated cryptic splice sites, new splice sites or pseudoexons (A), to promote the inclusion of 
an exon by targeting splicing regulatory sequences (B), to exclude an exonic sequence to either eliminate a nonsense 
mutation or restore the reading frame caused by a frameshift deletion (C), or to force the exclusion of an alternative 
exon or the selection of an alternative splice site (D). Based on(Hammond & Wood, 2011; Pérez et al., 2010; Siva et al., 
2014)   
 
1.3.5 U1 snRNA basic principles  
Since its discovery in the early days of splicing research, U1 snRNA has been 
recognised as a crucial player in the first stages of the splicing process (Lerner et al., 
1980; Mount et al., 1983; Rogers & Wall, 1980). U1 snRNA is a 164 nucleotides long 
molecule with a well-defined structure consisting of four stem–loops, which primarily 
exerts its function in the form of an ribonucleoprotein (RNP) complex (termed U1 
snRNP) containing seven Sm proteins and three U1-specific proteins U1A, U1C and 
U1-70k (West, 2012) (Figure 1.7A). It is now well-established that U1 snRNP initiates 
spliceosome assembly by binding to the 5' splice donor site (SDS) through base pairing 
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between the single stranded terminal sequence of the U1 snRNA molecule and the 
moderately conserved stretch of nucleotides at the 5' SDS (CAG/GURAGU; R-purine) 
marking the exon-intron boundary (Buratti & Baralle, 2010). However, not all base pairs 
at different 5’ ss positions are equally important, and their contribution to splicing 
roughly correlates with their conservation (Figure 1.7B). In the 9 nucleotides consensus 
sequence (which sometimes is expanded to include 11 base pairs), the most 
conserved 5’ ss positions lie at the first two intronic nucleotides (+1 and +2), which 
determine the 5’ ss subtype. The GU subtype, with Watson-Crick complementarity with 
A7 and C8 in U1, accounts for 99% of 5’ ss. The minor subtypes have a mismatch to 
U1 at either +1 or +2 and include the GC (0.9%) and the very rare AU 5’ ss recognised 
by the spliceosome. The next most conserved 5’ ss positions (>75% in humans) are -
1G (the last exonic nucleotide) and +5G, which form strong G-C base pairs with U1, 
with three hydrogen bonds. Consensus nucleotides -2A, +3A, +4A, and +6U are also 
conserved but have a lesser although important contribution to 5’ ss strength because 
their base pairing to U1 involves only the formation of two hydrogen bonds. The 5’ ss 
positions +7 and +8 do not exhibit substantial conservation in humans, yet several lines 
of evidence indicate that these positions can base-pair to U1 and contribute to splicing 
(Roca et al., 2013). Once the donor site does not always conform to the consensus 
sequence, but can instead have a degenerate pattern feature, it is understandable that 
many other additional elements such as splicing silencer and enhancer motifs, the 
presence of alternative splice sites, secondary structures and regulatory proteins can 
influence the splice site selection (Figure 1.7A) (Raponi & Baralle, 2008; Roca et al., 
2013).  
U1 snRNA is classically known for its role in pre-mRNA splicing events. However, 
the finding that U1 snRNA levels far exceed other spliceosomal associated snRNA 
levels led to the notion that it may have additional roles in the cell apart from splicing 
regulation (Guiro & O'Reilly, 2015; West, 2012). Indeed, emerging evidence suggests 
that U1 snRNA plays a key role in transcription initiation and in the protection of pre-
mRNAs from degradation, as also has a regulatory function in the 3’-end formation, 
protecting pre-mRNA transcripts against premature polyadenylation and contributing to 
the regulation of alternative polyadenylation (Guiro & O'Reilly, 2015; Spraggon & 
Cartegni, 2013; Valadkhan & Gunawardane, 2013; West, 2012). Furthermore, the 
binding of U1 snRNA to 5’ ss like sequences present in the 3’ untranslated region 
(UTR) of some mRNA sequences (eg. viral mRNA), can lead to the suppression of the 
polyadenylation process, resulting in mRNA degradation (Buratti & Baralle, 2010; 
Valadkhan & Gunawardane, 2013; West, 2012). 
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Figure 1.7: A) Role of U1 snRNP in splicing. The 5’ end of U1 snRNA base pairs to the 5’ ss, to define the functional 
SDS. The process is positively and negatively modulated by splicing factors binding to exonic and intronic splicing 
enhancer and silencers motifs (ESE, ISE, ESS, and ISS, respectively). B) The 5’ ss motif. The height of each nucleotide 
corresponds to its conservation at the corresponding position (-3 to -1 are exonic positions and +1 to +8 corresponds to 
intronic positions). Adapted from(Roca et al., 2013; Spraggon & Cartegni, 2013)  
 
1.3.6 U1 snRNA-mediated therapy 
Splicing mutations at the 5’ SDS, which are frequent among defects that cause 
human disease, compromise U1 snRNA binding and can prevent spliceosome 
assembly and subsequent splicing, which results in exon skipping, intron retention or 
activation of cryptic splice sites (Buratti et al., 2007; Roca et al., 2013). The most 
deleterious mutations at a 5’ ss are those affecting the nearly invariant GU dinucleotide 
at the positions +1 and +2. For the remaining nine positions the effects on splicing and 
consequently the possibility of causing disease are less clear. In fact, nucleotide 
substitutions affecting the less conserved positions can cause splicing defects in some 
but not all 5’ ss, suggesting that the remaining 5’ ss positions and/or the overall context 
dictate the extent to which splicing is disrupted (Roca et al., 2013; Roca et al., 2008). 
As donor splice site mutations disrupt the complementarity of the donor site with 
the endogenous U1 snRNA, restoring the complementarity through engineered 
modification of the U1 snRNA represents a valuable approach. For this purpose, the 
normal 5’ end sequence of the U1 snRNA cloned in a vector is substituted with a 
sequence complementary to the target mutated region, and the modified U1 snRNA 
gene is tested in appropriate splicing assays in an attempt to correct the splicing defect 
(Figure 1.8) (Havens et al., 2013; Pinotti et al., 2011).  
A 
B 
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Figure 1.8: Modified U1 snRNA compensation of 5’ ss mutations. Exogenous U1 snRNA with a compensatory mutation 
(black) allows for base-pairing with the 5’ ss and the restoration of exon recognition and inclusion. Based in(Havens et 
al., 2013)  
 
Once the U1 snRNA approach acts on the pre-mRNA level, it has the advantage 
of maintaining the expression regulation of the targeted gene in the normal 
chromosomal context. Also, given that the U1 snRNA gene used for splicing rescue 
includes promoter and regulatory sequences, it has the capability of guaranteeing long 
term correction of the genetic defect (Pinotti et al., 2011).   
In common with other rescue strategies based on targeting RNA by 
complementarity (e.g. AOs), modified U1 snRNAs have to deal with potential off-target 
effects that might affect splicing of other genes. This could be dangerous for modified 
U1 snRNAs that have only one base change from the natural U1 snRNA, and thus 
might activate normally silent cryptic donor splice sites and induce aberrant splicing in 
other genes (Pinotti et al., 2011). The consequences of such unwanted side reactions 
are hard to predict and depend on the gene function of the spliced transcript. However, 
screening and mapping of the binding site sequence against the human genome to 
exclude sequence homologies should widely reduce nonspecific events even though 
their complete elimination cannot be guaranteed. Therefore, experimental analysis 
should be performed whenever possible to test the effect of the U1 treatment on 
nontarget transcripts. In a mutation-adapted U1 snRNA approach to correct a 5’ 
splicing defect in Retinitis pigmentosa (RP) this type of test was performed to search 
for the presence of unwanted side effects. The splicing pattern of five RP-associated 
genes containing potential binding sites to a fully adapted U1 was analysed after U1 
treatment and no missplicing events were found in the nontarget transcripts (Glaus et 
al., 2011).  
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Additionally, to reduce the possible interaction of modified U1 snRNAs with non-
target 5’ SDSs, an interesting model of an adapted U1 snRNA called Exon-Specific U1 
(ExSpeU1) was developed. The ExSpeU1s have engineered 5’ tails that direct their 
loading onto non-conserved intronic regions downstream of the SDS of a specific exon, 
and are expected to improve specificity and reduce potential off-target effects 
(Fernandez Alanis et al., 2012; Pinotti et al., 2011). This novel strategy has been 
applied successfully in different studies allowing an efficient rescue of exon skipping 
due to different types of splicing mutations associated with defective exon definition, 
constituting therefore a possible approach for correction of 5’ splicing defects with less 
probable unwanted side effects (Dal Mas et al., 2015a; Dal Mas et al., 2015b; 
Fernandez Alanis et al., 2012). 
In the U1-mediated approach, the U1 snRNA gene must be incorporated into an 
expression vector and delivered to cells. In tissue culture experiments, the plasmid 
vector is usually delivered using cationic lipids as transfection agents (Sánchez-Alcudia 
et al., 2011), but the U1 snRNA gene can also be inserted in lentivirus and adeno-
associated virus (AAV) vectors to be delivered effectively into in vitro cell culture or in 
vivo animal models (Balestra et al., 2014; Schmid et al., 2011). However, the potential 
for antiviral immunity is still a major limitation of using viral vectors for therapy. Possible 
alternatives to viruses are exosomes, liposomes and nanoparticle delivery (Hammond 
& Wood, 2011). 
 
1.3.6.1 The use of U1 snRNA-mediated therapy to correct 5’ 
splice site defects 
Since the original observation that engineered U1 snRNA mutations can 
suppress 5' ss mutations (Zhuang & Weiner, 1986), modified U1 snRNAs have been 
assayed as a possible therapy for numerous diseases caused by 5’ ss mutations 
affecting different positions of the donor site. The great majority of the approaches was 
successfully performed using different modified-U1’s co-transfected along with 
minigenes or directly delivered into patients’ cells in diseases like Cystic fibrosis, 
Haemophilia B, SMA (Fernandez Alanis et al., 2012), Retinitis pigmentosa (Glaus et 
al., 2011; Tanner et al., 2009), Fanconi anemia (Hartmann et al., 2010; Mattioli et al., 
2014), Propionic acidemia (Sánchez-Alcudia et al., 2011), Bardet-Biedl syndrome 
(Schmid et al., 2011; Schmid et al., 2013) and Netherton syndrome (Dal Mas et al., 
2015a).  Modified U1’s also allowed to rescue splicing at mutated 5’ ss in mouse 
models of DMD (Denti et al., 2006), SMA (Dal Mas et al., 2015b) and Human 
coagulation factor VII (hFVII) deficiency (Balestra et al., 2014). Most of the U1 
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therapeutic reports did not comprise toxicity studies. However, in the study of Dal Mas 
and colleagues for SMA (Dal Mas et al., 2015b), the U1 (ExSpeU1) therapeutic effects 
were also tested in different cellular models and no toxicity was observed. Yet, in the 
recent in vivo study for hFVII (Balestra et al., 2014), the authors reported that the 
expression of a modified U1 snRNA was associated with hepatotoxicity in a dose-
dependent manner, which probably arose due to the binding of the engineered U1 to 
similar consensus 5’ ss in other genes. 
 
We must recognise that so far the extent of rescue of expression levels obtained 
with strategies targeting the RNA level has been only moderate. Moreover, the in vivo 
application of AOs and modified U1 snRNA depends on a safe and efficient delivery of 
oligonucleotides and expression cassettes. However, in the case of LSDs it can be 
argued that even a very low increase in enzymatic activity of lysosomal enzymes, 
would result in a significant amelioration of the patients’ clinical phenotype. Therefore, 
for these disorders, RNA-based therapeutic studies aimed at demonstrating their 
clinical translatability have been greatly encouraged.  
 
1.4. Challenges for delivery and the future of 
antisense therapy  
Despite the significant progresses achieved in the field of RNA-based therapies, 
their clinical application to rare genetic disorders such as IMDs remains limited due to a 
number of important constrains that still need to be overcome. Improvements in 
different fields of antisense technology will be fundamental to achieve a safe and 
effective systemic delivery of antisense agents to target tissues in different organs, 
ensuring prolonged therapeutic effects and absence of drug-induced toxicities. The 
establishment of proof of concept efficacy in IMD animal models of disease will be also 
mandatory to make possible the translation of antisense-mediated splicing modulation 
therapies to the clinical realm (Du & Gatti, 2009; Pérez et al., 2010; Pérez et al., 2014).  
As in several other IMDs, most LSDs include a clinical variant characterized by 
primary central nervous system (CNS) involvement. At present, control of the CNS 
manifestations remains a major challenge because of the inability to deliver therapeutic 
agents of large molecular weight across the intact BBB (Pastores, 2010). One way to 
solve this problem that was already used in animal models, is by the local injection in 
the desired brain region or by injections in the cerebrospinal fluid if broad distribution in 
the brain is deemed more important (Zalachoras et al., 2011). However, given the 
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invasive character of this methodology and since the treatment of neurodegenerative 
disorders with antisense drugs may require life-long repeated dosing, it would be highly 
preferable to be able to administer such agents systemically. Strategies to improve 
brain uptake after peripheral delivery are being assayed, including increasing the 
permeability of the BBB, complexing or conjugating to cationic nanoparticles or CPPs, 
encapsulation in liposomes conjugated to monoclonal antibodies, or use of exosomes, 
constituting a promise for the delivery of antisense molecules to CNS tissues (Douglas 
& Wood, 2013; Pérez et al., 2014). Nevertheless, more studies are needed to optimize 
these strategies or find new others that in a near future could allow not only the 
transport of different antisense drugs across the BBB as also their body-wide 
distribution through noninvasive systemic delivery protocols. Clearly, systemic delivery 
would be the choice for diseases involving multiorgan pathology as is the case of the 
majority of LSDs and several other IMDs.  
Another hurdle that is delaying the recognition of antisense drugs as effective 
therapeutics is related to the number of affected patients necessary to conduct robust 
clinical trials. If in several pre-mRNA processing diseases there is a sufficient number 
of affected patients (Rigo, 2014), in rare genetic disorders like IMDs, the mutations 
found in clinical practice, including those affecting splicing, are largely “private” 
mutations present in only one or few patients, which in some cases may compromise 
the development of clinical trials (Douglas & Wood, 2011; Pérez et al., 2014). 
Additionally, if every new antisense designed sequence is classed as a novel 
therapeutic agent, it will be unfeasible to subject each one individually to all the 
rigorous drug development tests and trials used in current pharmaceutical practice. 
These are two of the major challenges facing personalized medicine that must be soon 
resolved to derive the full benefit promised by AO-based therapies (Douglas & Wood, 
2011). To achieve that, concerted efforts must be fostered and the drug regulatory 
processes must also be adapted to encompass these new medicines. A possibility that 
is being discussed is to treat all AOs as a unique drug class, rather than considering 
the specific sequences for each case, which would help to eliminate an important 
obstacle in the current pipeline of the development of antisense drugs (Douglas & 
Wood, 2013; Lee & Yokota, 2013; Pérez et al., 2010).  
 
 
 
 
 
 
66 FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 2 
OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
69 
 
 
With the recognition of the importance of splicing defects in human disease has 
come the realization that constitutive and regulated splicing reactions are potential 
therapeutic targets. This is stimulating the development of new therapeutic approaches 
to modify or eliminate an mRNA bearing a disease-causing mutation. Therefore, in 
many rare genetic disorders for which there is to date no effective treatment, the 
emergence of RNA-based approaches constitutes a powerful alternative or adjunct 
therapeutic strategy. 
Also, an understanding of the mechanisms through which splicing mutations are 
associated to disease together with the increase of the knowledge about the 
mechanisms that underlie pre-mRNA splicing regulation is being crucial to disclose 
new therapeutic targets and approaches. 
 
In this context, the present work had, as major goals, the genetic analysis and 
splicing mechanisms comprehension of a panel of gene mutations involved in the 
pathogenesis of LSDs as well as the design and application of splicing therapeutic 
approaches.  
  
More specifically the following objectives were set: 
 
1. To refine the knowledge on the genetic mechanisms disrupted by a number of LSDs 
splicing mutations previously selected for study.  
 
2. To identify the cis and trans-acting factors altered in the presence of the splicing 
mutations under study, applying both in silico bioinformatic analyses and in vitro 
functional studies, thus contributing to a better understanding of the role of specific 
sequences and proteins in the regulation of the splicing process in general. 
 
3. To design and develop splicing therapeutic approaches (antisense-U1 snRNAs and 
antisense oligonucleotides) for the selected LSDs splicing mutations and to provide the 
in vitro proof of concept that exploring such strategies would result in splicing 
correction.  
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Synopsis 
 
Background and motivation for the study 
 
For the last years our group has been working on the genetic characterization of 
several LSDs. One of the various studies performed focused on a group of patients 
with MPS II, a LSD caused by mutations in the IDS gene, which led to the identification 
of a considerable number of mutations that impair the normal splicing process of the 
gene. A wide range of splicing alterations was observed in the presence of the different 
mutations. Some occurred at the conventional 5’ and 3’ ss, having a rather quite 
predictable outcome, but others had an exonic location (like missense and nonsense 
mutations) and were further proven to be less typical splicing mutations since they 
affected the normal splicing pattern due to the creation or disruption of cis-acting 
sequence elements. These observations in addition to the fact that for the IDS gene 
several alternative transcripts are annotated in Vega Genome Browser (http://vega.sa 
nger.ac.uk/) pointed to a complex regulation of the splicing of some regions of this 
gene that probably required the interaction of several auxiliary SREs. The IDS gene 
seemed therefore to be a good model to deepen the analysis of disrupted splicing 
mechanisms and its disease-related phenotypes. Indeed, a substantial part of the 
knowledge on the molecular mechanisms that regulate splicing has been provided by 
functional studies of specific mutations, as they represent an important field on 
observation to clarify which elements are disturbed by their presence, ultimately 
contributing to a better knowledge of the splicing process in general.  
Under these grounds, we decided to analyse two mutations in IDS exon 3. A 
missense mutation (c.257C>T; p.P86L) for which the impact on splicing was already 
known (Alves et al., 2006) and a nonsense mutation (c.241C>T, p.Q81X) that we also 
suspected to be implicated in the deregulation of the IDS exon 3 splicing. The main 
questions we wanted to address were why and how was the splicing affected by these 
mutations.  
We additionally studied another IDS gene mutation, a synonymous mutation 
located in exon 8 (c.1122C>T) whose pathogenicity was previously associated with a 
splicing alteration. The c.1122C>T leads to the creation of a new 5’ ss inside exon 8 
with a higher score than the normal 5’ ss. Regarding this mutation, our main interest 
was to develop a splicing therapeutic strategy using AOs to neutralize the use of the 
new splice site and restore the normal splicing of exon 8. 
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Study design and methods overview 
- Evaluation of the splicing mechanism of each disease-causing mutation through
cDNA analysis and minigene reporter vector functional studies.
- In silico identification of the cis-acting elements and trans-acting splicing factor
proteins that were altered in the presence of the mutations in exon 3.
- Elaboration of depletion (RNA interference) and overexpression assays of specific
predicted SR and hnRNP proteins to analyse if their binding to cis-acting motifs
correlated with the ability to affect splicing of the IDS exon 3.
- Design and construction, by site-directed mutagenesis, of an IDS minigene construct
appropriate to assess if the specific cis-acting motifs found in silico were related to the
splicing pattern alteration on exon 3.
- Exploration of AOs therapy (AMO and LNA oligonucleotide) to correct the splicing
defect caused by the synonymous mutation on exon 8 of IDS gene in patient
fibroblasts.
Major results 
We have achieved a better comprehension about the molecular mechanisms 
regulating IDS gene splicing. Additionally, a hypothetical model for the regulation of the 
constitutive splicing mechanism around the 3′ ss of IDS exon 3 was proposed.  
The application of the antisense therapeutic strategy to correct the splicing defect 
caused by the exonic mutation c.1122C>T was not successful. Besides the need of 
additional experiments, the results so far obtained indicate that the application of this 
type of therapies may be particularly difficult for mutations located in gene regions 
under complex splicing regulation. 
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Synopsis 
Background and motivation for the study 
This study involved the development of innovative therapeutic strategies for 
Sanfilippo C splicing mutations. Sanfilippo C or MPS IIIC is a very rare LSD caused by 
mutations in the HGSNAT, a gene that was cloned in 2006 (Hrebícek et al., 2006). 
Since then, many molecular defects associated to MPS IIIC have been reported 
worldwide. The Portuguese MPS IIIC patients were molecularly characterised by our 
group and two splicing mutations were reported: c.372-2A>G (Coutinho et al., 2008) 
and c.234+1G>A (unpublished data). In this work two distinct therapeutic approaches 
were developed for different splicing mutations in the HGSNAT gene, one potentially 
able to correct effects at the RNA level (using modified U1 snRNAs) and the other one 
at the protein level (using chaperones). Therefore, the target mutations were previously 
evaluated in terms of those that could be corrected at RNA level and those whose 
effect could be ameliorated at protein level. The first group included three nucleotide 
changes affecting distinct 5’ SDSs (c.234+1G>A, c.633+1G>A and c.1542+4dupA) and 
the second group only had one mutation affecting a 3’ acceptor splice site (c.372-
2A>G).  
The study was performed in collaboration with two research groups also working 
in MPS IIIC, the group of Professor Daniel Grinberg from the University of Barcelona, 
Spain and the group of Professor Alexey Pshezhetsky from the University of Montreal, 
Canada. Our group together with the group of Professor Daniel Grinberg was 
dedicated to the application of modified U1 snRNAs therapeutic approaches for the 
correction of the mutations c.234+1G>A, c.633+1G>A and c.1542+4dupA. The group 
of Professor Alexey Pshezhetsky was involved in the use of a pharmacological 
chaperone (glucosamine) to correct the aberrant folding of a mutant HGSNAT protein 
lacking 4 amino acids that was encoded from an abnormal splicing transcript originated 
in the presence of the mutation c.372-2A>G. 
Study design and methods overview 
- Construction of minigene reporter vectors for each donor site mutation under study
and their transfection in COS-7 cells (Portuguese and Spanish groups).
- Construction through site-directed mutagenesis of different U1 snRNA vectors
adapted to each mutated SDS under study (Portuguese group).
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- Development of U1 snRNA therapeutic approaches for the correction of the different
5’ SDS mutations in HGSNAT, both through the transfection of the different adapted U1
vectors along with the mutation-disease minigenes in COS-7 cells as well as directly in
control and patients’ fibroblasts (Portuguese and Spanish groups).
- Assessment of the effect of a pharmacological chaperone in the correction of the
aberrant folding of a mutant protein with the loss of four amino acids (Canadian group).
Major results 
A partial correction of the splicing pattern (almost 50%) was achieved for the 
c.234+1G>A mutation with the application of a modified U1 snRNA that completely
matched the mutant SDS in fibroblasts of patients carrying this mutation, which is one
of the most prevalent MPS IIIC causing mutations in Spanish and Portuguese patients.
For the mutations c.633+1G>A and c.1542+4dupA, no rescue was observed after the
modified U1 snRNAs overexpression in patients’ cells.
Moreover, the glucosamine treatment resulted in an increase in the enzymatic 
activity, indicating a partial recovery of the correct folding. Nevertheless, as this part of 
the study goes beyond the scope of this thesis, the obtained results will not be 
mentioned or discussed in the other sections of this thesis.  
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antisense therapy. 
Submitted 
116 FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
117 
Synopsis 
Background and motivation for the study 
Our therapeutic target in this study was the c.66G>A mutation present in the 
CSTB gene, which encodes the protein cystatin B. Cystatin B is an inhibitor of several 
papain-family cysteine proteases, cathepsins, which have a key role as lysosomal 
enzymes (Merwick et al., 2012). The main function of cathepsins is the non-selective 
degradation of intracellular proteins, but they also participate in antigen processing and 
apoptosis (Lehesjoki & Gardiner, 2012).  
Mutations in the CSTB gene are responsible for the Unverricht-Lundborg disease 
(ULD), an autosomal recessive neurodegenerative disorder also known as progressive 
myoclonic epilepsy type 1 (EPM1) (Joensuu et al., 2008).  
Some of the symptoms presented by ULD patients, such as myoclonus, epilepsy 
and progressive neurologic deterioration are also observed in some LSDs like the 
NCL’s, Sialidosis type I and Neuronopathic Gaucher disease, which explains the 
classification as lysosome-related progressive myoclonic epilepsies (Ramachandran et 
al., 2009). This means that, whilst screening for LSDs in patients with that sort of 
symptoms, we may come across cases of different aetiology. The case that caught our 
attention was an ULD patient homozygous for a new synonymous mutation (c.66G>A; 
p.Q22Q) located at the last nucleotide of CSTB exon 1. It affects the 5’ SDS of exon 1,
as was evidenced by cDNA analysis that allowed the identification of two splice
variants, one of normal size with the G>A change and other with partial inclusion of
intron 1 due to the activation of a cryptic splice site inside the intronic sequence. Since
this mutation is a synonymous change that impairs normal splicing, it appeared to be a
good candidate for correction through RNA therapeutic approaches, having been
therefore considered for splicing correction in the scope of this study. Two different
RNA-based therapeutic strategies were tested: mutation-adapted U1 constructs with
increased complementarity to the mutated SDS of exon 1 and AOs (LNA
oligonucleotide) specifically designed to block the activated cryptic splice site in CSTB
intron 1.
Study design and methods overview 
- Design and construction through site-directed mutagenesis of the different U1 snRNA
vectors adapted to the mutated SDS of exon 1.
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- Test the efficacy on splicing pattern correction of the different mutation-adapted U1
snRNA vectors through their transfection in patient fibroblasts.
- Test the efficacy on splicing pattern correction of the LNA oligonucleotide designed to
block the activated cryptic splice site in CSTB intron 1 through its transfection in patient
fibroblasts.
Major results 
A successful correction of the aberrant splicing pattern using a LNA 
oligonucleotide that blocked the use of the cryptic intronic splice site was achieved. 
Using adapted U1 vectors with increased complementarity to the mutated splice 
site, no correction of the aberrant splicing pattern was observed. 
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Abstract 
Unverricht-Lundborg disease (ULD) is a common form of progressive myoclonic 
epilepsy caused by mutations in the cystatin B gene (CSTB) that encodes an inhibitor of 
several lysosomal cathepsins. Presently, only pharmacological treatment and psychosocial 
support is available for ULD patients. Although the dodecamer expansion in the promoter 
region of the CSTB gene is the most common cause associated to ULD, a patient without 
the expansion mutation but homozygous for a unique splice defect was identified in 
Portugal. This case seemed to provide a good model for testing the feasibility of splicing 
correction. Therefore, to overcome the effect of the CSTB splicing mutation c.66G>A (exon 
1), we investigated two strategies for the correction of the defect in patient’s cells. One 
attempt relied on the use of U1 snRNA mediated correction and involved the generation of 
three constructs with increasing complementarity to the splice donor site of CSTB exon 1. 
In the other strategy used, a specific locked nucleic acid (LNA) antisense oligonucleotide 
was designed to block a cryptic 5’ splice site in intron 1. This latter LNA oligonucleotide 
approach allowed the restoration of the normal splicing pattern and the recovery was 
sequence and dose-specific. The failure of the U1 snRNA therapeutic approach may rely 
on the scarce knowledge on how the correct splicing in the exon 1 of CSTB occurs, 
evidence has suggested that it depends not only on the U1 complementarity, but probably 
also on enhancer splicing factors.  
This work constitutes a proof of concept for correcting a CSTB RNA defect involved 
in ULD with a mutation-specific antisense approach. It contributes to the growing evidence 
on the feasibility of this type of potential therapy. The insights here obtained make 
mutation-based correction a candidate for personalized treatment of patients with this type 
of mutation, encouraging similar investigations in other genetic diseases.  
 
Graphical Abstract 
Efficient correction of the aberrant splicing pattern in the fibroblasts of a patient with Unverricht-Lundborg 
disease using a locked nucleic acid oligonucleotide.   
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Introduction  
Unverricht-Lundborg disease (ULD), also known as progressive myoclonic 
epilepsy type 1 (EPM1), is an autosomal recessive neurodegenerative disorder 
characterized by young-onset stimulus sensitive myoclonus and tonic-clonic seizures.1 
Although occurring worldwide, it shows the highest prevalence in Finland, North Africa 
and the Western Mediterranean region.2 Presently, symptomatic pharmacologic and 
rehabilitative management are the mainstay of patient care.2,3 
ULD is caused by mutations in the CSTB gene, localized on chromosome 
21q22.34, which encodes cystatin B, a protease inhibitor that in vitro has shown the 
ability to inhibit several lysosomal cysteine proteases, known as cathepsins, by tight 
reversible binding.5 
Up to now, thirteen CSTB mutations have been described as causal of EPM1 
(HGMD®Professional 2015.3 Release), the most common of which is an unstable 
expansion of a dodecamer repeat in the promoter region6 that down-regulates CSTB 
mRNA levels.7 The remaining mutations are missense, nonsense, frameshift and splice 
site (ss) mutations that lead to abnormal RNA processing (HGMD®Professional 2015.3 
Release).  
The increasing knowledge of RNA biology is stimulating the development of new 
approaches relying on RNA-based strategies to modify or eliminate mRNA bearing 
disease-causing mutations. On one hand, the use of U1 snRNA complementary to the 
mutated splice-site has become an attractive strategy to correct 5’ss defects in U1 
binding, as shown for the PCCA8, RPGR9 and BBS110 genes. On the other hand, 
oligonucleotide-based approaches are also emerging as efficient alternatives that can 
be employed in the future as new treatments for a number of diseases. Currently, 
several strategies are already under investigation for many conditions, including 
Duchenne muscular dystrophy11, spinal muscular atrophy12, β-Thalassaemia13 and 
pyridoxine dependent epilepsy14, as well as for Alzheimer15, Parkinson16, Huntington17 
and other neurodegenerative diseases.18 
Recently, our group described a Portuguese ULD patient who is homozygous for 
a new synonymous mutation (c.66G>A; p.Q22Q; r.[66g>a,65_66ins66+354pb]) which 
leads to missplicing of CSTB pre-mRNA.19 Two transcripts were found in the patient-
derived fibroblasts, a normal transcript with the synonymous G>A change at the last 
nucleotide of exon 1 and a mutant one including 354 bp of intron 1 due to the activation 
of a cryptic 5’ splice site, which predicts an abnormal peptide with a premature 
truncation. Nevertheless, in terms of protein, no abnormal peptide was previously 
described as being detected. Although the presence of the normal and aberrant 
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transcripts is consistent, only the decreased amount of normal protein was established, 
and if an abnormal peptide does exists its level may be below resolution limits. In this 
work, we have explored both antisense oligonucleotide and U1 snRNA mediated 
strategies in an attempt to correct the splice defect associated with the c.66G>A splice 
donor site mutation in patient’s cells. We report that the use of a specific locked nucleic 
acid (LNA) antisense oligonucleotide, designed to block the activated cryptic splice site 
in intron 1, succeeded to restore the normal splicing pattern since only the normal 
transcript was then produced. 
Although most ULD patients have the dodecamer expansion, and would not be 
candidates for this approach, the experiment here described demonstrates the 
feasibility of LNA correction in the particular case under study and may provide 
evidence for its potential use in other cases with similar mutations. As far as we know 
this is the first report of a patient-tailored genetic lesion correction in cells from an 
individual with ULD.  
 
Material and methods 
Biological material 
A Portuguese patient with a clinical diagnosis of ULD was previously reported to 
be homozygous for the c.66G>A change in the CSTB gene, in a study where the 
mutation effects at mRNA and protein levels were also analyzed.19 Skin fibroblasts 
were obtained from the patient and one healthy control with appropriate informed 
consent. For all the samples confidentiality of personal data were protected. Both 
fibroblast cells were cultured and expanded following standard procedures in DMEM 
medium (Gibco Invitrogen, Carlsbad, USA) with 10% FBS and 1% kanamycin at 37°C 
and 5% CO2. Average cell viability and proliferation was assessed at each passage, 
and at each experimental treatment, by the trypan blue vital dye exclusion test. 
 
Cycloheximide treatment of control and patient fibroblasts  
To perform the nonsense-mediated mRNA decay (NMD) assays, both fibroblast 
cells were cultured in the presence of two different concentrations of cycloheximide 
(100 and 600 µg/ml) for 8 hours. Total RNA was then isolated using the High Pure RNA 
Isolation kit (Roche Applied Science, Indianapolis, USA) and reverse-transcribed using 
the “Ready-To-Go You-prime first-strand beads” kit (GE Healthcare, Buckinghamshire, 
UK) following the manufacturer’s protocols. Specific primers for exon 1 (Fw: 5’-
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GCCGAGACCCAGCACATC-3’) and exon 2 (Rv: 5’-TGACACGGCCTTAAACACAG-3’) 
were used to amplify cDNA fragments encompassing the wild-type (WT) and the 
mutation region where the CSTB gene splicing was altered as described in Pinto et 
al..19 After RT-PCR amplification and electrophoretic separation, the obtained bands 
were cut and purified using the Wizard® SV Gel and PCR clean-up system (Promega, 
Madison, USA) and then sequenced. 
 
U1 snRNA constructs treatment and analysis 
The pG3U1 vector, which includes the sequence coding for human U120 (kindly 
provided by Dr. F. Pagani) was used to express the wild-type U1 snRNA (U1-WT). The 
different mutant U1 constructs (U1-CSTB-mut; U1-CSTB-wt and U1-CSTB-tc)  adapted 
to the mutant splice donor site (SDS) of CSTB exon 1 were generated by site direct 
mutagenesis using the QuikChange® Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA) according to the manufacturer’s instructions. PCR 
reactions were performed with specific primers for each construct. The U1-CSTB-mut 
construct was obtained using primers U1-mut-F (5’-GATCTCATACTTACTTGGCAGG 
GGAGATAC-3’) and U1-mut-R (5’-GTATCTCCCCTGCCAAGTAAGTATGAGATC-3’), 
the U1-CSTB-wt was generated with the primers U1-wt-F (5’-GATCTCCCACCCACCT 
GGCAGGGGAGATAC-3’) and U1-wt-R (5’-GTATCTCCCCTGCCAGGTGGGTGGGA 
GATC-3’) and for the U1-CSTB-tc construct we used the primers U1-tc-F (5’-
GAGGCCCAAGATCTCCCACCCACTTGGCAGGGGAG-3’) and U1-tc-R (5’-CTCCCC 
TGCCAAGTGGGTGGGAGATCTTGGGCCTC-3’). The presence of the mutation under 
investigation (Figure 2A) was confirmed by sequence analysis.  
To perform the U1 snRNA treatment, both healthy control and patient fibroblast 
cells at 90% of confluence were transfected in 6-well plates with 2.5, 3.5 or 4.5 µg of 
each modified U1 snRNA using either Lipofectamine 2000 or LTX (Invitrogen, 
Carlsbad, USA) according to the manufacturer’s instructions. The electroporation 
technique with the 4D-Nucleofector kit (Lonza, Basel, Switzerland) was also employed. 
In parallel, to estimate transfection efficiency, healthy control and patient cells were 
transfected with a control plasmid encoding GFP and fluorescent cells were monitored 
by microscopy. After 24 h or 48 h of transfection cells were harvested and total RNA 
was isolated using the High Pure RNA Isolation kit (Roche Applied Science, 
Indianapolis, USA). Conversion into cDNA and RT-PCR analysis was done as 
mentioned above.  
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Antisense oligonucleotide treatment and analysis  
The antisense locked nucleic acid (LNA) oligonucleotide targeted to the donor 
cryptic splice site in the CSTB intron 1 was designed, synthesized and purified by 
Exiqon (Vedbaek, Denmark). The sequence of the LNA used is: 5’ 
AGCCGGCTGCTCACCTGCGCCATCGCCG 3’, as shown in Figure 3A. For the LNA 
treatment, between 2.5 and 3.5x105 fibroblast cells were grown in 6-well plates and 
after 16 h treated with different concentrations of LNA (5, 25, 50 and 100 nM) using 
Lipofectamine LTX (Invitrogen, Carlsbad, USA) as delivery reagent. Cells were 
harvested 24 h later, total RNA was isolated and cDNA synthesized as described 
above. The RT-PCR analysis of the patient derived transcripts was performed using 
the primers described above.  
 
CSTB Protein Immunodetection  
For Western Blot analysis, between 1.4 and 1.6x106 patient fibroblast cells grown 
in 75 cm2 flasks were transfected with 100 nM of LNA using Lipofectamine LTX 
(Invitrogen, Carlsbad, USA) and harvested after 24 h. Total protein extracts, obtained 
from patient fibroblasts with and without LNA treatment, as well as from a healthy 
control sample without treatment, were homogenized in a lysis buffer solution 
(supplemented with a protease inhibitor cocktail) and ruptured by three cycles of 5 
minute freeze thawing and then briefly centrifuged. Protein concentration was 
determined measuring the absorbance at 280 nm in a NanoDrop® ND-1000 
Spectrophotometer. Equal amounts of total protein crude extracts were loaded on a 4-
12% NuPAGE® Novex® Bis-Tris precast gel (Invitrogen, Carlsbad, USA). After 
electrophoresis, proteins were transferred to a nitrocellulose membrane in a semi-dry 
transfer system for 2 h at 150 mA. Ponceau staining was used to monitor equal loading 
of protein. Immunodetection was carried out using anti-Stefin B antibody (mouse 
monoclonal IgG1 reacting with human Stefin B: ab54566 from Abcam – Cambridge 
Science Park, UK) followed by an incubation with goat anti-mouse IgG-HRP as the 
secondary antibody (sc-2005, Santa Cruz Biotechnology, CA). Total amount of protein 
loaded was controlled by incubation with monoclonal anti-α-tubulin antibody (T6199 – 
Sigma-Aldrich, St.Gallen, Switzerland). The protein signal was developed using the 
Enhanced Chemiluminescence System (GE Healthcare, Buckinghamshire, UK).  
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Results: 
The CSTB c.66G>A mutation generates one aberrant transcript in ULD 
patient 
The CSTB transcription profile was obtained by RT-PCR and showed an aberrant 
transcript present in patient but not in control fibroblasts. To determine whether the 
expression level of this or other aberrant transcripts were altered by NMD, healthy 
control and patient fibroblasts were treated with two concentrations of cycloheximide 
(100 or 600 µg/ml) for a period of eight hours. As shown in Figure 1, no extra band or 
increased expression was observed in addition to the previously described transcripts. 
Direct sequencing of the bands confirmed the sequence pattern originally described in 
Pinto et al..19 These experiments indicated that the CSTB c.66G>A mutation generates 
one aberrant transcript that is not degraded by NMD.  
 
 
 
 
 
 
 
 
Figure 1: RT-PCR amplification of RNA extracted from control and patient fibroblasts untreated and treated with two 
different concentrations of cycloheximide (100 and 600 µg/ml) for 8 hours. M – molecular marker; NC – negative control; 
HC – healthy control; P – patient.  
 
U1 snRNA therapeutic approach in patient cells 
Since the recognition of the splice donor site occurs essentially through U1 
snRNA complementary base pairing to the 5’ splice site21, any mutation in the SDS can 
disturb the U1 binding and consequently induce aberrant splicing.  Here, we were 
dealing with exon 1 of the CSTB gene, wherein its 5´ splice site is complementary to 
the 5´end of the U1 snRNA in 7 out of the 9 consensus positions at the exon-intron 
border (Figure 2A). Mutation c.66G>A introduces a mismatch in the consensus G 
position at -1 of the exon, thus lowering the complementarity to U1 snRNA. Given 
these features, we sought to restore normal CSTB splicing through the generation of 
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mutant U1 expression constructs with increased complementarity to the mutated SDS 
of exon 1. Three different mutation-specific U1 adaptations were generated (Figure 
2A): U1-CSTB-mut, which compensates only for the c.66G>A mutation; U1-CSTB-wt, 
which matches all 11 nucleotides of the wild-type CSTB SDS of exon 1; and U1-CSTB-
tc engineered to match all 11 nucleotides of the mutated SDS. To control for the effect 
of the adaptations, the U1-WT expression construct was also used (Figure 2A). 
After 24 h or 48 h of transfection with the different U1 constructs, RT-PCR 
analysis showed that in the case of the ULD patient cells, no changes occurred in the 
endogenous CSTB splicing pattern regardless of the types and concentrations of U1 
isoforms tested. Also, in the control cell line none of the U1 variants concentrations 
tested induced alterations in normal CSTB splicing and only correctly spliced 
transcripts were detected (Figure 2B). The identity of the amplified bands was 
confirmed by sequencing analysis.  
To discard the hypothesis of poor fibroblasts transfection efficiency as a possible 
cause for the negative results achieved, a fluorescence GFP vector was transfected in 
parallel and an efficient acquisition of the vector was observed. Furthermore, the 
electroporation technique was also tried but no improvement in transfection efficiency 
was achieved and the same results were obtained (data not shown).  
 
Figure 2: U1 snRNA-mediated Gene Therapeutic Approach in ULD patient-derived fibroblasts. A) Molecular base-
pairing between the 5’ end of the different U1 constructs and the wild-type and mutant splice donor sites of CSTB exon 
1. The position of the mutation c.66G>A is highlighted in dark grey. Additionally to the construct expressing the U1-WT, 
the three different U1 variants generated: U1-CSTB-mut (-1T), U1-CSTB-wt (+3C;+4C;+7C;+8C) and U1-CTSB-tc (-
1T;+3C;+4C;+7C;+8C) are represented. The U1 snRNA sequence changes are illustrated in bold. B) RT-PCR analysis 
of control and ULD patient cells untreated and after treatment with 2.5 µg of the different U1 constructs. Neither the U1-
WT construct nor the three U1 variants tested showed any effect on CSTB exon 1 splicing. The same result was 
observed when overexpression of 3.5 or 4.5 µg of each adapted U1 was performed (data not shown). The healthy 
control normal splicing pattern was not altered after transfection of the various U1 adaptations. M – molecular marker; 
NC – negative control; NT – no treatment; mut – mutant; wt – wild-type; tc – totally complementary.  
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Correction of CSTB mutation-induced missplicing using a LNA 
oligonucleotide in patient-derived fibroblasts 
As an alternative approach to correct CSTB exon 1 splicing, a specific 28-mer 
locked nucleic acid (LNA) oligonucleotide was used to block the activated cryptic 5’ 
splice site within intron 1 (Figure 3A). Different quantities of the LNA were transfected 
in patient fibroblasts and then the endogenously spliced CSTB transcripts from 24 h 
treated cells were submitted to RT-PCR. The cDNA pattern showed that treatment with 
increasing amounts of LNA abolished the aberrantly spliced transcript with the insertion 
of 354 bp of intron 1 in a dose-dependent manner, with total correction being achieved 
at 100 nM of LNA (Figure 3B).  
In order to analyze whether the observed splicing correction led to alteration of 
cystatin B protein levels, the protein was detected by Western blot in untreated control 
fibroblasts and in patient fibroblasts treated with 100 nM of the specific LNA. The 
Western blot protein analysis (Figure 3C) revealed the presence of a band with 11 kDa, 
which corresponds to the normal CSTB protein in control (untreated with LNA) and 
patient fibroblasts (treated and untreated with LNA). The treatment seems therefore not 
to interfere with CSTB protein expression. The abnormal truncated protein was not 
detected in patient fibroblasts, suggesting low amounts of protein below the detection 
limit of the antibody.  
 
Figure 3: Antisense locked nucleic acid (LNA) therapeutic approach in ULD patient-derived fibroblasts. A) Schematic 
representation of the splicing downregulation observed in the presence of the c.66G>A CSTB mutation. The sequence 
of the LNA complementary to the cryptic donor site activated by the mutation and used in order to block the recognition 
of the intronic alternative 5’ splice site in fibroblasts from the patient is shown. B) Transcriptional profile obtained for 
healthy control (HC) and patient fibroblasts untreated (0 nM) and treated with quantities between 5 to 100 nM of LNA 
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oligonucleotide. The RT-PCR analysis showed the disappearance of the aberrantly spliced transcript (451 bp) when 
cells were treated with 100 nM of the LNA oligonucleotide. Correctly spliced mRNA was obtained 24 h after transfection 
in a dose-dependent manner. C) CSTB protein expression in control and patient fibroblasts untreated (0 nM) and 
treated with 100 nM of the LNA. The Alfa-tubulin protein was used as loading control. M – molecular marker; NC – 
negative control; HC – healthy control.  
 
Discussion 
RNA missplicing diseases account for up to 15% of all inherited diseases, 
including neurological, myogenic and metabolic disorders.22 
Mutations affecting splicing have been often neglected, either because they 
appear to be silent synonymous changes with no effect on amino acid sequence, or 
due to their misleadingly innocent intronic location. However, with the increasing 
knowledge arising from fine cDNA analysis and genomic sequencing of patients 
suffering from a wide range of diseases, the number of known exonic or intronic 
mutations that affect splicing has increased to 50-60% of all annotated disease-causing 
mutations.23 It is therefore understandable that during the last decade, genetic therapy 
directed toward correction of RNA missplicing has progressed from theoretical work in 
cultured cells to promising clinical trials.22  
In this work, in order to mitigate the splice defect present in a ULD Portuguese 
patient, we have developed and tested both antisense oligonucleotide and U1 snRNA 
mediated therapeutic strategies. Endogenous U1 snRNA is a major component of the 
spliceosome which targets 5’ splice site introns within poly (A) pre-mRNAs in a 
sequence-specific manner recruiting the splicing machinery. The modification of U1 
snRNA to increase complementarity affinities to mutated splice donor sites is being 
explored to correct 5’ splice site defects dependent on U1 binding. In parallel, modified 
Antisense Oligonucleotides (AOs) that hybridize by complementarity to a selected site 
in the pre-mRNA have been also used to redirect splicing allowing restoration of the 
gene function.24,25 
The ULD patient here addressed was homozygous for c.66G>A, a mutation that 
does not alter the coding amino acid sequence (p.Q22Q), but instead activates a 
cryptic splice site downstream in CSTB intron 1, probably because its presence 
weakens the recognition of the normal splice donor site by the U1. An aberrant 
transcript with the inclusion of 354 bp of intron 1 is produced and was found to escape 
nonsense-mediated mRNA decay since, as shown in figure 1, upon treatment with 
cycloheximide, the intensity of the expressed transcript did not increased. Since the 
transcript is not degraded, it is predictable that it will give rise to a truncated protein 
with only 36 amino acids, 13 of them not present in the normal CSTB protein that is 
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made up of 98 residues. At least in the patient fibroblasts, the normal transcript is also 
generated and normal CSTB protein is expressed although at lower levels than in 
control cells (Figure 3C). This raises the possibility that the cause of the disease in the 
patient can be the combined effect of the reduced levels of the normal CSTB protein 
and the production of a truncated protein that possibly exerts a toxic or dominant 
negative role, as it was evidenced for other CSTB mutant proteins.26,27 Recent data 
indicated that EPM1 mutants that affect protein sequence are prone to aggregate in 
cells, without being clear whether the proteins misfolding and aggregation are 
responsible for augmenting progression of the disease and neurodegenerative 
changes or whether it is the lack of the protein’s function, or a combination of both.26 It 
was also found that in ULD patients who are compound heterozygous bearing the 
dodecamer expansion in the promoter region together with a point or indel mutation, 
the clinical features are more severe than in patients homozygous for the dodecamer 
expansion, a genotype simply associated with low CSTB protein levels.28,29 This finding 
further reinforces that mutant EPM1 proteins can indeed modulate disease phenotype 
by a toxic gain of function,26,27 which, as a plausible hypothesis, may happen with the 
aberrant protein associated with the mutation c.66G>A. In any case, our reasoning was 
that the elimination of the aberrant transcript and consequently of the abnormal protein 
would represent a key step toward a personalized therapeutic correction for this 
patient. Furthermore, since transcript splicing patterns in other cell types may differ 
from the pattern observed in fibroblasts, the possibility of a different ratio of normal 
versus truncated transcript still remains as a plausible explanation for the disease and 
a target amenable by this type of approach.  
The first attempt here report relied on the U1 strategy and failed to correct the 
aberrant transcript. Since the rescue of splicing mutations in the last base of the exon 
has been achieved using U1 construct isoforms10,30, the lack of success in the case of 
c.66G>A suggests that the mutation might affect splicing through mechanisms that are 
not only dependent of the U1 complementarity. This interpretation gains support from 
previous studies31,32 where mutations affecting the 5’ splice site of TCIRG1 and BBS1 
genes were demonstrated to have different rescue efficiencies after treatment with U1 
mutant vectors, providing evidence that mutations close to the GT donor sites are 
mechanistically different. Symptomatically, according to the in silico predictions before 
performed19 in the WT context of CSTB exon 1, the constitutive 5’ splice site presented 
a lower score value (0.78) than the downstream cryptic splice site (0.98) only used in 
the presence of the G>A change. This observation suggests that the constitutive splice 
donor site recognition depends not only on the U1 snRNA binding, but also on other 
splicing factors that could interact with the CSTB pre-mRNA privileging the 5’ canonical 
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use. In fact, the analysis of the exon 1 sequence by the ESEfinder and ESRsearch 
software’s33,34 predicted the presence of ESE binding motifs (CGACCAG or GACCAG) 
in the WT terminal region of exon 1 that were no longer recognized when the G>A 
change is present, also pointing to an involvement of specific SR proteins in the 
recognition of the WT exon 1 donor site. Therefore, the failure of the U1 snRNA 
therapeutic approach in neutralizing the effect of c.66G>A may be explained by the 
complexity of the CSTB exon 1 donor site splicing regulation, which might depend not 
only on the U1 complementarity, but also on the presence of enhancer splicing factors 
that were disturbed by the mutation.  
As an alternative strategy to suppress the splicing defect, we used a specific LNA 
oligonucleotide to block the activated cryptic splice site in intron 1, which effectively 
abolished the aberrant splicing process of CSTB pre-mRNA in patient-derived cells. 
The normal splicing pattern leading to a single transcript with the synonymous change 
G>A was successfully rescued and so the therapeutic effect was expected to be 
achieved. Furthermore, the recovery was sequence and dose-specific (Figure 3B). In 
this way, this work adds evidence on the feasibility of antisense therapy, joining the 
many studies that are paving the way for translating the technology into the clinical 
practice.35-39  
In conclusion, this work points to the promising in vitro correction of a CSTB 
protein defect causing ULD with a mutation-specific antisense therapy. Further studies 
are needed to assess the therapeutic potential of AOs, including how they could be 
delivered to specific organs and tissues without limitations. Even so, the insights 
obtained from this study make mutation-based therapy a clear candidate for 
personalized treatment of ULD patients encouraging similar investigations in other 
genetic diseases.  
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3.5 Ongoing work 
Development of U1 snRNA-mediated therapeutic strategies to 
correct 5’ splice site defects in Mucopolysaccharidosis I and 
Mucolipidosis III alpha/beta  
In the context of this work, we have begun to explore the use of antisense U1 
snRNA-mediated therapeutic strategies to correct two 5’ ss mutations reported in 
patients with MPS I and Mucolipidosis type III alpha/beta (ML III alpha/beta). The 
selected mutations were c.1650+5G>A (IDUA gene) and c.3335+6T>G (GNPTAB 
gene), which affect the 5’ ss positions +5 and +6, respectively, and were considered 
good candidates for the application of this type of therapeutic approach. 
MPS I is an autosomal recessive disease caused by the deficiency of the enzyme 
α-L-iduronidase that can result in a wide range of phenotypic involvement, usually 
classified in three major clinical entities: Hurler (OMIM# 607014), Hurler-Scheie 
(OMIM# 607015), and Scheie (OMIM# 607016) syndromes. All of them are caused by 
mutations in the IDUA gene (Neufeld & Muenzer, 2001). Currently, HSCT and ERT 
using laronidase (Aldurazyme®) are the two available therapeutic options for MPS I 
that, however, still present some limitations (Coutinho et al., 2012; Cox, 2012).  
ML IIII alpha/beta (OMIM# 252600) is an autosomal recessive disease caused by 
mutations in the GNPTAB gene. This gene encodes the α-and β-subunits of the N-
acetylglucosamine (GlcNAc)-1-phosphotransferase, an enzyme that plays a key role in 
the formation of mannose-6-phosphate residues on lysosomal enzymes required for 
efficient transport to lysosomes (Kornfeld & Sly, 2001). Mutations in the GNPTAB gene 
can also cause a more severe form of mucolipidosis, the ML II alpha/beta (OMIM# 
252500), whilst mutations in the GNPTG gene, which encodes another subunit of the 
same enzyme (γ subunit), are associated with the milder ML III gamma (OMIM# 
252605) (Raas-Rothschild et al., 2000; Tiede et al., 2005). Both types of mucolipidoses 
are rare LSDs which share similar clinical features, including skeletal abnormalities. 
Since to date, no causal therapies are available for the treatment of patients, the 
management of the disease is essentially symptomatic (Raas-Rothschild et al., 2012). 
According to the information contained in the Human Gene Mutation Database 
(HGMD® Professional 2015.3), splicing mutations are frequent genetic defects in MPS 
I and ML II and III alpha/beta amounting to ~ 16 % and 10 %, respectively. From these, 
~ 64 % in MPS I and 47 % in ML II and III alpha/beta correspond to 5' SDS mutations, 
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thus constituting a vast target repertory for mutation specific U1 snRNA-mediated 
therapeutic approaches. 
The mutations addressed in this work, c.1650+5G>A in the IDUA gene and 
c.3335+6T>G in the GNPTAB gene, were found in a MPS I and ML III alpha/beta 
patient’s respectively. Both mutations were already described as well as was 
deciphered their impact in splicing (Kudo et al., 2006; Venturi et al., 2002). 
Fibroblast samples from the two patients were obtained from the biobank of 
Institute G. Gaslini, in the scope of a collaborative work with Doctor Mirella Filocamo 
(Genova – Italy). The MPS I patient is a compound heterozygous for a nonsense 
mutation (c.1205G>A; p.W402X) and the 5’ ss mutation c.1650+5G>A in intron 11 of 
IDUA responsible for the skipping of exon 11. The ML III alpha/beta patient is also a 
compound heterozygous for a missense mutation (c.2864C>T; p.A955V) and the 5´ ss 
mutation c.3335+6T>G in the intron 17 of GNPTAB whose presence leads to the 
skipping of the exon 17 (Table 3.1; Figure 3.1 A and B).   
 
Table 3.1: Genotypes of the MPS I and ML III alpha/beta affected patients.  
Patient Allele 1 Allele 2 Location Reference 
P1 (MPS I) c.1650+5G>A c.1205G>A (p.W402X) Intron 11/Exon 9 
(Venturi et al., 2002) / 
(Scott et al., 1992) 
P2 (ML III alpha/beta) c.3335+6T>G c.2864C>T (p.A955V)  Intron 17/Exon 14 
(Kudo et al., 2006) / 
(Zarghooni & Dittakavi, 
2009) 
P1 – patient 1; P2 – patient 2  
 
 
 
 
 
 
 
Figure 3.1: Agarose gel showing the transcripts observed in control (C) and in patients (P1 and P2) together with 
schematic views of each transcript’s constitution. A) Patient P1 (MPS I) carries a 5’ ss mutation located on intron 11 of 
the IDUA gene (c.1650+5G>A) and a nonsense change on exon 9 (c.1205G>A; p.W402X). IDUA transcripts were 
amplified between exons 9 and 12 and the transcriptional pattern showed three bands: one corresponding to the 
skipping of exon 11 transcribed from the allele bearing the donor site change c.1650+5G>A (lower band), a normal band 
arising from the allele with the nonsense mutation (p.W402X) (upper band) and an heteroduplex extra product 
(intermediate band – black arrow). The healthy control showed a single amplified band of normal molecular weight. B) 
Patient P2 (ML III alpha/beta) carries a donor site mutation located on intron 17 of the GNPTAB gene (c.3335+6T>G) 
and a missense mutation (pA955V) on exon 14. For the amplification of the GNPTAB transcripts primers for exons 13 
A 
M NC C P1 
500 bp 
200 bp 
Heteroduplex 
B 
M NC C P2 
800 bp 
500 bp 
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and 18 were used and the RT-PCR pattern showed a smaller band with the skipping of exon 17 resulting from the 5’ ss 
change c.3335+6T>G, and a larger one with normal molecular weight from the allele bearing the missense change. The 
healthy control showed a single amplified band of normal molecular weight.  Sequencing results of the obtained 
products are illustrated by schematic drawings. M – molecular marker; NC – negative control; C – control; P1 and P2 – 
patient 1 and 2 respectively.  
 
To proceed with the development of the antisense-snRNA therapeutic strategies 
for both mutations, an analysis was performed to identify the specific base pairing 
between the U1 snRNA cDNA sequence and the wild-type (WT) and mutant 5’ ss of 
IDUA exon 11/intron 11 and GNPTAB exon 17/intron 17. (Figure 3.2 A1 and B1). 
Subsequently, to construct the different U1 snRNA mutation-adapted vectors, to bind 
specifically to both mutant SDSs, the pG3U1 vector (Lund & Dahlberg, 1984) was 
modified through mutagenesis. For the IDUA mutation three different U1 variants were 
constructed (U1 IDUA mut 1 – complementary to +5; U1 IDUA mut 2 – complementary 
to +2; U1 IDUA mut 3 – totally complementary to the SDS) (Figure 3.2 A2) and for 
GNPTAB mutation two U1 mutant vectors were constructed (U1 GNPTAB mut 1 – 
complementary to +6; U1 GNPTAB mut 2 – totally complementary to the SDS) (Figure 
3.2 B2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1 
3’ U1 WT 
IDUA exon 11 
mutant SDS 
5’ Exon 11 
Splice donor site 
CAGgcaaaugg… 
GUCcauucaua 
X 
3’ U1 WT 
IDUA exon 11 
WT SDS 
5’ Exon 11 
Splice donor site 
CAGgcaagugg… 
GUCcauucaua 
Increased complementarity to the SDS 
A2 
a) 
Exon 11 
mutant SDS 
U1 IDUA 
mut 1 
5’...CAGgcaaaugg... 
3’...GUCcauutaua... 
c) 
Exon 11 
mutant SDS 
U1 IDUA 
mut 3 
5’...CAGgcaaaugg... 
3’...GUCcguuuacc..
. 
b) 
Exon 11 
mutant SDS 
U1 IDUA 
mut 2 
5’...CAGgcaaaugg... 
3’...GUCcguucaua... 
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Figure 3.2: A1 and B1) Schematic representation of base-pair interactions between the U1 snRNA and the WT and 
mutant SDSs of exon 11 and exon 17 of IDUA and GNPTAB genes, respectively. A2 and B2) Illustration of the strategy 
followed to increase the complementarity of U1 snRNA with the mutated SDS of IDUA and GNPTAB genes. U1 
complementarity was increased stepwise, and to try to compensate for the IDUA mutation at position +5, three different 
U1-adaptations were designed [U1 IDUA mut 1 (+5T) – A2a; U1 IDUA mut 2 (+2G) – A2b and U1 IDUA mut 3 (+2G; 
+5T; +7C; +8C) – A2c], whereas for the GNPTAB mutation at position +6, two different U1-adaptations were engineered 
[U1 GNPTAB mut 1 (+6C) – B2a and U1 GNPTAB mut 2 (-3A; +6C; +8C) – B2b]. Upper case letters show exonic 
nucleotides, whereas the lower case letters denote intronic nucleotides. Base-pairing is indicated by vertical lines and its 
loss by an X. The mutant nucleotide is highlighted in red and the changed nucleotides in the U1 sequence are illustrated 
in green.  
 
Finally, to achieve therapeutic functional rescue of the mutations under study, 
different amounts (between 2.5 µg and 4.5 µg) of the U1 WT vector (as control) and of 
the different mutation-adapted U1 vectors were transfected using Lipofectamine LTX 
(Invitrogen) into control, MPS I and ML III alpha/beta patients’ fibroblasts for 24 h or 48 
h. After transfection, the RT-PCR analysis of control samples for both cases revealed 
that the WT splicing pattern was not affected by any of the U1 isoforms (Figure 3.3 A1 
and B1). For patient samples, the skipping of exon 11 (Figure 3.3 A1) and of exon 17 
(Figure 3.3 B1) generated by the mutated allele in the SDS positions +5 and +6 
respectively, was still observed. Additionally, in both cases the gel band corresponding 
to the transcript with the normal length was excised, purified and sequenced, in order 
to check if in the nucleotide positions where the nonsense (IDUA) and missense 
(GNPTAB) mutations occur, the WT bases were also present. Their presence would 
B1 
3’ U1 WT 
GNPTAB 
exon 17 
WT SDS Splice donor site 
5’ Exon 17 UAGguaaguag… 
GUCcauucaua 3’ 
Splice donor site 
5’ Exon 17 
U1 WT 
GNPTAB 
exon 17 
mutant SDS 
UAGguaaggag… 
GUCcauucaua 
X 
B2 
a) 
Exon 17 mutant SDS 
U1 GNPTAB mut 1 
5’...UAGguaaggag... 
3’...GUCcauuccua... 
b) 
Exon 17 mutant SDS 
U1 GNPTAB mut 2 
5’...UAGguaaggag... 
3’...AUCcauuccuc... 
Increased complementarity to the SDS 
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To the best of our knowledge, there is no successful report of U1 snRNA 
therapeutic approaches for mutations at position +6. However, it is important to 
mention that in a study of Schmid and coworkers (Schmid et al., 2013) an attempt was 
carried out to investigate the effect on splicing of a +6 mutation and its possible 
correction through U1-based therapy. To evaluate the effect of different sequence 
alterations on splicing of the exon 5 SDS of BBS1 gene, minigenes mutated at nine 
positions (between -3 and +6) were generated. Specifically, for the +6 mutation no 
alteration in the normal splicing pattern was observed after the expression of the 
mutated minigene. Despite this result, the authors performed the co-transfection of the 
+6 mutant minigene along with two different modified U1’s, though, as expected, no 
effect on splicing was observed.  
In the current work the transfection of different U1 adaptations in patients’ 
fibroblasts with the c.1650+5G>A (IDUA gene) and c.3335+6T>G (GNPTAB gene) 
mutations did not rescued the induced aberrant splicing patterns. It is of note that the 
U1’s transfection was associated with a high level of cell death, which could be due to 
the presence of the modified U1’s, but we cannot rule out that it may also have arisen 
due to the cells contact with the chemical reagent Lipofectamine used for transfection. 
This observation led us to hypothesize that low transfection efficiency may have 
occurred compromising an efficient acquisition of the different U1’s by the cells.  
In order to understand if the absence of aberrant splicing correction was indeed 
related with low transfection efficiency, we intend to perform further investigations. At 
first, we plan to co-transfect the different U1 modifications with WT and +5 and +6 
mutant minigenes (already constructed) into an established continuous cell line (e.g. 
COS-7). Since these cells generally allow good transfection efficacy, its use could help 
to disclose easily possible splicing pattern changes due to the U1’s adaptations. In a 
further approach, we pretend to implement in our laboratory the viral transduction 
technique in order to test the mutation therapeutic rescue through the AAV or lentiviral 
treatment of patients’ fibroblasts with the different U1 variants. Viral vectors are 
considered more efficient and less toxic than other delivery systems, minimizing cell 
death and side effects that usually come along with transfection due to the use of 
chemical reagents. The viral transduction of U1 constructs in patients’ fibroblasts was 
applied successfully in some diseases allowing the total or partial recovery of 
misspliced transcripts (Glaus et al., 2011; Hartmann et al., 2010; Schmid et al., 2011). 
Additionally, it would be interesting to test the effects of the U6 snRNA in a similar 
way to the one tested for the U1 snRNA. The U6 has been described as essential for 
an accurate splicing process. After U1 dissociation, the correct recognition of the exon 
at 5’ ss is assured through the interaction of the U6 snRNA with nucleotides at 
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positions +4 to +6 of the SDSs (Kandels-Lewis & Séraphin, 1993; Lesser & Guthrie, 
1993). In the recent study of Schmid et al. (Schmid et al., 2013), involving a mutation 
affecting the +5 position of the donor site, the partial correction of aberrant splicing was 
only achieved using modified U1 vectors. The authors evaluated the effect of several 
adaptations of the U6 snRNA sequence for its correction, having found out that only a 
co-application of adapted U1 and U6 isoforms corrected the splice defect caused by 
the mutation at SDS position +5. The sequence complementarity between U6 and the 
three SDS positions (+4, +5, and +6) showed to be relevant for the outcome of the 
therapy.  
Extrapolating these results for the mutations at positions +5 and +6 that we are 
studying, it would be important to also test the effect of mutation-adapted U6 isoforms 
in the correction of the splicing defects, given its importance in the interaction with the 
affected donor site positions during the splicing process. 
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4.1 Functional analysis and splicing mechanisms 
comprehension of exonic variants on IDS gene  
Exonic point mutations can create or disrupt cis-acting sequence elements (e.g. 
ESEs or ESSs) thus affecting splicing. A significant proportion of these mutations may 
consequently have a wide range of effects, which, however, are very difficult to predict. 
In this study, the analysis of IDS splicing patterns in the presence of the mutation 
c.241C>T, previously classified as a conventional nonsense mutation (Brusius-Facchin 
et al., 2014), allowed us to verify that this mutation also affects the normal splicing 
process of the IDS gene. Furthermore, the functional analysis of reporter minigenes for 
this mutation and for two other exonic mutations on IDS gene, c.257C>T and 
c.1122C>T, previously characterized at the cDNA level, further confirmed its 
involvement on the deregulation of splicing in the IDS gene. Therefore, an accurate 
characterization of genetic mutations able to clarify the link between genotype and 
phenotype cannot be restricted to the examination of gDNA. Unless cDNA analysis is 
also conducted, simple classifications as synonymous, missense or nonsense 
mutations can mitigate the fact that a mutation may also generate severe, 
unconventional splicing alterations. In this way, the results obtained in this study 
reinforce the importance of analysing all exonic variations that predictably can induce 
any effect on splicing, not only through cDNA analysis but also through other analytical 
tools such as the use of minigenes. 
In addition, exonic mutations that cause defective splicing can give important 
lessons for understanding exon-identity determinants and AS mechanisms. In this 
study, the in silico analysis of the splicing mutation c.257C>T located on IDS exon 3 
allowed to identify changes in putative binding motifs for some SR and hnRNP trans-
acting proteins. The functional analysis through protein splicing factors overexpression 
or depletion assays and through cis-acting motifs loss of function minigene studies 
validated the bioinformatic predictions, confirming that the detected changes in cis-
acting motifs are related to the splicing pattern alterations observed. Further, the 
functional experiments also demonstrated that the SRSF2 and hnRNP E1 proteins are 
involved in the use and repression of the constitutive 3’ ss of exon 3, respectively.  
Globally, this study contributed to a deeper understanding of the molecular basis 
of IDS gene splicing regulation through the identification of critical SREs with effects on 
splicing, as also provided the basis to propose an explanatory model for the splicing 
regulation around the IDS exon 3 region. This kind of exploratory studies encourages 
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similar approaches in other genes, which hopefully will further increase the knowledge 
about the pre-mRNA splicing. 
4.2 Development of antisense oligonucleotides and 
U1 snRNA-mediated therapeutic strategies  
Synonymous mutations that alter splicing are suitable targets for AO therapy 
given that once corrected the splicing defect the restored transcript will allow normal 
protein production. In this work, for the synonymous mutations c.1122C>T and 
c.66G>A that impair the normal splicing process of IDS and CSTB genes respectively, 
we have investigated the applicability of RNA-based therapies to revert the caused 
splicing defects.  
For the c.1122C>T change present in a MPS II patient, which creates a new 5’ ss 
within exon 8 giving rise to a transcript shorter than usual, the use of four different AOs 
(three AMOs and one LNA) did not correct the aberrant splicing in patient cells. 
Instead, it led to the production of a new abnormal splicing product with the total 
skipping of exon 8. Given this result, we reasoned that the AOs could be masking 
some exonic motifs potentially involved in the inclusion of exon 8 in the mature 
transcript. In fact, an in silico analysis predicted the existence of several putative cis-
binding motifs for trans-acting proteins in the mutated region. Additionally, AOs 
transfection experiments performed in control fibroblasts resulted in a change of the 
normal splicing pattern towards aberrant forms, including the exon 8 skipping observed 
in patient cells after treatment, further demonstrating that the AOs are indeed masking 
relevant motifs for the 5’ ss regulation of exon 8. Altogether these observations support 
the conclusion that the efficacy of AO therapy greatly depends on the genomic 
environment.  
Given the “silent” effect of this splicing mutation and the potential of AOs for the 
correction of this kind of variants, it will be important to continue the search for an 
optimal AO that effectively corrects the aberrant splicing. A suitable approach to find 
that AO involves the design of an AO microwalk at a single nucleotide resolution along 
the entire length of IDS exon 8, with the subsequent test of all resulting AOs in patient 
fibroblasts. If the correction is successfully achieved at RNA and protein levels, the 
further development of in vivo studies using an animal model will also be mandatory for 
the translation of this approach into the clinic.  
The c.66G>A mutation was described in CSTB gene in a patient with ULD. ULD 
is a lysosome-related progressive myoclonic epilepsy for which the pathophysiologic 
mechanism is still not completely understood, even though it might be underlain by loss 
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or gain of function mechanisms (Lehtinen et al., 2009; Polajnar et al., 2012). This 
synonymous mutation, leads to missplicing of CSTB pre-mRNA, generating a normal 
transcript with the synonymous G>A change at the last nucleotide of exon 1 and a 
mutant one with a partial inclusion of intron 1, due to the activation of a cryptic 5’ ss. 
This aberrant transcript does not seem to be a target of the NMD mechanism as shown 
by cycloheximide experiments, indicating that a truncated protein may be produced. 
So, in this case the disease can result from the reduced expression of the normal 
CSTB protein in combination with the presence of a mutant truncated protein with a 
possible toxic role. To try to overcome the consequences of this splicing defect, we 
used a specific LNA oligonucleotide that effectively blocked the activated cryptic splice 
site in intron 1, resulting in the recovery of the normal splicing pattern of a single 
transcript with the synonymous change G>A. Hence, this work represents the in vitro 
proof of concept that AOs can be used to overcome the effect of this CSTB splicing 
mutation. Currently, only symptomatic pharmacologic and rehabilitative management 
are available for the treatment of ULD patients. So, a therapy based on mRNA 
correction would be a desirable alternative, although only applicable to a small number 
of patients, because, despite the high frequency (~31%) of splicing mutations 
described in CSTB (HGMD® professional release 2015.3), only two of the reported 
mutations, including the one here studied (Kagitani-Shimono et al., 2002; Pinto et al., 
2012), would profit from AOs mutation-based therapy, since the others affect canonical 
splice sites. It is possible that more research on innovative therapeutic options, as well 
as more reports on in vitro/in vivo studies to overcome this pathology, help draw further 
attention to ULD, encouraging clinicians to refer additional cases of epilepsies of 
unknown aetiology to be screened for CSTB defects, potentially increasing the number 
of diagnosed mutations suitable for correction through this kind of therapy.  
Having been here demonstrated the mutation correction at the RNA level, future 
studies addressing the clarification of its impact at protein level will be fundamental. 
The use of an antibody specifically designed for the detection of the mutant CSTB 
protein will lead to a more accurate analysis of the CSTB protein profile before and 
after the AO treatment, which certainly would afford a more comprehensive picture 
about the effect of the c.66G>A mutation at the protein level, and, consequently, about 
the effect of the treatment strategy. Again, for the effective development of the therapy 
it will also be essential to conduct in vivo studies. 
Another major issue in this work was to explore the potential of U1 snRNA-
mediated therapies. Once this approach had been previously used to rescue splicing 
mutations in the last base of an exon, we also tried to apply it to the just before 
mentioned c.66G>A in CSTB, given its location in the last nucleotide of exon 1 of the 
148 FCUP 
Splicing therapeutics for patients affected by lysosomal storage disorders 
 
gene. Still, in this case, the correction of the abnormal transcript in the patient cells was 
not achieved. The data obtained from the in silico analyses actually explains this 
negative result once it showed that the 5’ canonical splice site presents a lower score 
than the 5’ downstream cryptic splice site and the predicted ESE binding motifs at the 
end region of the WT exon 1 were altered in the presence of the c.66G>A mutation. 
These predictions support the hypothesis that the proper recognition of the CSTB exon 
1 may depend, not only from the U1 complementarity but also from other splicing 
factors interacting with the pre-mRNA, which probably compromised the success of the 
U1 approach for this mutation.  
Modified U1 snRNAs were also used as an effort to correct donor site splicing 
defects in HGSNAT, namely those which concerned the 5’ ss mutations c.234+1G>A, 
c.633+1G>A and c.1542+4dupA affecting four different MPS IIIC patients.  
In a first optimization approach where the effect of the overexpression of different 
designed U1 snRNAs on the splicing process was tested on minigenes bearing each 
specific donor site mutation, no correction of the aberrant splicing was observed. In 
fact, despite the skipping of each respective exon was corrected, the transcript 
generated after treatment was still aberrant due to the use of cryptic “gt” donor sites 
situated at intronic positions +5 and +6 (c.234+1G>A and c.633+1G>A mutations) or 
+6 and +7 (c.1542+4dupA mutation) which was promoted, partially or completely, by 
some adapted U1 snRNAs. Despite the absence of correction, and given that 
minigenes do not entirely reproduce the human cellular environment, the different U1 
variants were also tested directly into patients’ fibroblasts. In the case of the 
c.633+1G>A and c.1542+4dupA mutations, the normal endogenous splicing process 
was not recovered after the overexpression of the different modified U1 snRNAs. For 
the c.234+1G>A mutation present in homozygosity in two patients, the overexpression 
of a modified U1 that completely matched the mutated 5’ ss allowed to achieve a partial 
recovery (almost 50%) of the splicing process, together with the use of the cryptic “gt” 
site at intronic positions + 5 and +6. This was an unexpected and surprising positive 
result, since the majority of the mutations localized in the high conserved nucleotide 
positions +1 and +2 of the SDS that were submitted to correction with modified U1 
snRNAs were not successfully rescued (Fernandez Alanis et al., 2012; Schmid et al., 
2013). To the best of our knowledge, the partial rescue of a +1 splice site mutation was 
reported only once, but in a case in which the mutated allele already produced some 
degree of the normal spliced transcript before treatment (Hartmann et al., 2010). So, in 
our study, we present the first case where a partial recovery of the normal splicing was 
achieved for a +1 mutation that did not produce any WT spliced mRNA when 
untreated. In this case, given the partial recovery of the correctly spliced mRNA, a 
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measurement of the enzymatic activity in patients’ cells after treatment was performed 
to analyse the effect of the partial splicing correction in protein function. However, no 
increase in enzyme activity level was observed, indicating that possibly a higher level 
of recovery of the splicing process is required to enhance the enzymatic activity.   
Whilst in this study we have added evidence that modified U1 snRNAs hold the 
potential to be used in the treatment of +1 donor site mutations, the results also pointed 
out that the success of the therapy would depend on the presence of other “gt” 
dinucleotides in the donor site region which, depending on the context, may be used as 
an alternative splice site interfering with the correction of the splicing process. 
Concerning the c.234+1G>A mutation, given that the overexpression of a totally 
complementary U1 snRNA promoted the utilization of an alternative splice site at 
positions +5 and +6, and taking into account the role of U6 snRNA in the recognition of 
the 5’ ss, in the near future it would be interesting to check whether the effect of 
modified U6 snRNAs alone or in combination with modified U1 snRNAs could 
specifically improve the use of the mutated site and not the alternative one, allowing 
the total correction of the 5’ ss defect. Once this is achieved, in vivo approaches should 
be designed. Recently, Balestra and colleagues (Balestra et al., 2014) described a 
novel methodology to generate mice expressing a 5’ ss defect for the coagulation 
factor VII, through liver-directed expression by plasmid or recombinant AAV vector 
administration. For those mice, subsequent injection of a modified U1 vector allowed 
the correction of an exogenous mutant construct. Thus, for this HGSNAT mutation it 
should be analysed the possibility of developing a similar approach in order to provide 
an in vivo proof of concept that this kind of therapy may be used for the correction of 
this MPS IIIC donor site splicing defect.  
Finally, we also have begun the development of U1 snRNA therapeutic 
approaches to correct two other mutations that affect the recognition of the 5’ ss, the 
c.1650+5G>A in the IDUA gene and c.3335+6T>G in the GNPTAB gene, causing MPS 
I and ML III alpha/beta, respectively. Different modified U1 snRNAs were transfected in 
patients’ fibroblasts, but no rescue of the normal splicing process was observed. 
Despite these preliminary results, this study is still ongoing and further experiments 
such as the co-transfection of the different U1 modifications with WT and +5 and +6 
mutant minigenes, the transduction in patients’ cells of the U1 variants using viral 
vectors as well as the study of the effect of different U6 snRNA modifications are 
already planned to find out the potential of antisense-U1snRNA therapy for these donor 
site mutations. 
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The implementation in our laboratory of the methodologies for the correction of 
splicing mutations using RNA-based therapies was also one of the important 
achievements of this work, once it opens the possibility of their application in future 
studies. 
Overall, this work allowed the identification of specific SREs involved in the 
splicing regulation of a particular region of the IDS gene, contributing not only to extend 
the knowledge about the mechanisms underlying the splicing of this gene but also of 
the splicing process in general. Additionally, the in vitro development of specific 
antisense therapeutic strategies to correct different splicing defects in LSDs was 
successfully achieved, leading to a better understanding of mutation-based therapies, 
and pointing them out as a feasible way to reach the personalized treatment of LSDs 
patients. These findings further encourage the investigation of similar approaches in 
other rare genetic diseases. 
To conclude, we would like to remember that science is a constant step-by-step 
construction. Our hope is that studies like this might seed the grounds to others that 
taking advantage on small lessons can proceed to in vivo approaches and use 
additional analytical methods to gain a comprehensive picture of the potential 
application of splicing therapeutics not only to LSDs but also to other genetic disorders. 
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